How To Hack A Poptropica Account

Loving Husband and wife or loved

are a newly married young couple spending the weekend at home, she is preparing dinner her husband and expected as staring with his elbows on his luxurious dining room. The only sound is the ticking of a clock nineteenth century European. She comes over and serves dinner. He sighs deeply and exhale slowly as complaining.

"Honey, why you behave as if we have an eternity to be married? - It tells Giselle Renato.

- Because we have an eternity to be married! "He said Renato surprised that his wife did not know.

- Really? I did not know forever is composed of just three months. And to think that there are marriages that last to be married even years! That is many eternities Do not you love? What would your romantic I are together for ever and ever. But tell me why that attitude of depressed teen, I know you better than yourself and that's not the reason for your dismay.

Giselle "Listen, I always thought that when we married, it would be very happy next to you. Not only I knew, I knew well told me, that's what worried me most. And now I'm married, I realize that everything they said is true. I'm terribly happy next to you. Now that's a problem. Your flaw is that you're perfect, it already had told Luciano before I met you. But there was a part of me that had the hope that there is some flaw in you. Sometimes I dreamed of the day I would make life a nightmare, would try to steal my wealth, my life would end in a divorce which would precipitate a major scandal, but every day I am more convinced than ever come to pass. And it sometimes saddens me a bit. I would love the opportunity to be able to be left in ruins because of an incredibly beautiful woman like you.

"Honey, trust me I do the best I can but it is difficult for someone suspected of a woman as smart as I am. also be unable to cheat, I think that fine art is for them men. But I married you because I knew from the beginning you serious exception. You would be unable to betray me because I love her more than yourself. I know from before we met.

- How do you know? I did everything possible to not love you realized it was you, at least until I confessed to you for that lie of yours in which you make me believe you were engaged to someone else.

Raziel Tovar

December 5, 2008

How Long Is Deer Sausage Good In The Refrigerator

say the most important thing in life is to love and be loved. In my case I always prefer the latter. But I also like love, but not enough to be loved. More hate experience these two situations simultaneously. I've been in this situation grape double time in my life, and found that there is nothing as bad as the feeling that one is completely happy. No I do not like happiness, it makes me happy. There is nothing beautiful and much less artistic in something like that. Happy endings so depressed me. When you're happy you have the sense of being whole and complete. So hard in that state could I turn my feelings into something poetic or musical. I've always preferred the tragedy. Living life should be the greatest of tragedies. Like when he's in love with beautiful eyes for which one has never been looked at. Or when it is committed to someone who loves you passionately, but are unable to close their eyes when they kiss. Unfortunately all is doomed to a predictable and tragic happy ending which is death. What a joy it is for many to know that one day will not experience more pain sensations. Instead I would have eternal life and never die. But that would be the tragedy that a man could have. Living over a thousand years and see how each generation dies you love or worse for that love you.

Matlab Plp R2007b Plp

The Artist and the Madness

know madness is needed to create art. Each artist must find his own madness, and once achieved it has to get back to reality in order to translate this. I try to find my madness, although I've done. So I think that only a fool would find crazy, so maybe I'm already crazy. But only sane person would realize that not crazy. And I know so I'm not. Now you need to be crazy to want to be crazy, then think what is not and once again believe that it is crazy. Only an artist could get to madness and back reality to write their experience with this. Maybe being crazy is to be in a world where everything is insane and unhealthy, but there is someone crazy enough to talk to them about the real world, reality, and of course in that place that person is seen as doubly crazy.

13/Nov/2008

How Often Do Nhl Players Get New Gloves

CHEMICAL PROJECT HUMAN GENOME ORT

Research in Molecular Biochemistry and Proteomics 2008

For the fourth year students in their final year of the specialty Chemical Technical School ORT Argentina made their final projects at various universities and with i ESEARCH recognized professionals. The working methodology avoids the didactic transposition allowing students to make their final activity where the project is being generated.

The relationship between the average and the graduate school is sponsored by the CONICET (National Research Council Science and Technology).

research projects for the current year are:

• Evaluation of the expression of adhesion molecule epithelial cadherin in human normal and tumor tissues. Investigator: Dr. Monica Vazquez-Levin. Institute of Molecular Biology and Medicine (IBYME-CONICET). Students: Yael Dobzewicz, Gala Szapiro.
  http://www.proyecto-6q.blogspot.com/
  
  
• action of hexachlorobenzene (HCB) on uroporphyrinogen decarboxylase of a human hepatocyte cell line. Mechanism of action. Investigator: Dr. María del Carmen Ríos de Molina. Biological Chemistry Department, Faculty of Natural Sciences. Students: Lucas Toiw, Uriel Frid.
  http://www.proyectofrid-toiw08.blogspot.com/
  
  
• Experimental models of metabolic diseases: porphyria and Metabolic Syndrome. Proteomics and Metabolomics of these disturbances. Investigator: Dr. Martha White Mazzetti. Biological Chemistry Department, Faculty of Natural Sciences (UBA). Students: Maria Duperron, Mauro Elencwajg.
  http://proyectofinal6q.blogspot.com/
  
  
• Hemodynamic Factors not related to the genesis and evolution of proteinuria in progressive renal disease. Investigator: Dr. Elsa Zotta. Pathogenesis Laboratory, Department of Physiology, Faculty of Medicine, UBA. Students: Barbara Helueni, Melanie Naiman.
  http://www.proyectoq08.blogpsot.com/
  
  
• Study of the involvement of anandamide in the regulation of sperm-ovioducto interaction in a bovine model. Investigator: Dr. Silvia Perez Martinez. School of Medicine - UBA. Students: Judith Arenas Tenenbaum, Melissa Braverman.
  http://www.scienceproject08.blogspot.com/
  
  
• study the molecular mechanisms involved in regulating gene of Saccharomyces cervisiae UGA4 in response to changes in nutrient availability with elucidate the different signaling cascades triggered by these nutrients and to establish their interconnections. Investigator: Dr. Susana Correa García. Biological Chemistry Department, Faculty of Natural Sciences, University of Buenos Aires. Students: Ivan Mikiej, Victoria Salama.
  http://www.proyectoquimica22.blogspot.com/
  
  
• Diagnosis of Von Willebrand disease (VWD) type 2N by phenotypic and genotypic techniques. Dr. Adriana I. Woods. Institute of Hematologic Research "Mariano R. Castex" of the National Academy of Medicine. Student: Abigail Skverer, Daniel Lin.
  http://www.vwd-diagnostico.blogspot.com/
  
  
• study of myelinogenesis in the peripheral nervous system in physiological and pathological conditions. Pluripotent cell involvement in the process of degeneration, nerve regeneration. Investigator: Dr. Patricia Setton-Avruj. Dept of Biological Chemistry, Faculty of Pharmacy and Biochemistry (IQUIFIB-UBA-CONICET). Students: Averbuj Daniel, Eitan Rozenszajn.
  http://www.proyectoaverbuj-rozenszajn.blogspot.com/
  
  
• Design and development of tumor vaccines using bacteria and tumor cells modified with genes inmunomodiladores. Study of immune mechanisms induced. Researcher: Claudia I. Waldner and Claudia Mongini. Laboratory of Cellular and Molecular Immunology. Center for Pharmacological and Botanical Studies (CEFYBO. CONICET-UBA). Pupils Surijón Amalia, Maria Belen Tolava Rivero.
  Http://www.amibeluproyecto.blogspot.com/
  
  
• cancer-associated genetic markers. Investigator: Dr. Javier Hernán Cotignola. Laboratory of Cancer and Apoptosis, Department of Biological Chemistry, Faculty of Natural Sciences at the University of Buenos Aires. Students: Ayelén Marano, Solange Perchik.
  http://www.marcadoresgeneticos.blogspot.com/
  
  
• Expression channel conductance of the cystic fibrosis transmembrane regulator (CFTR) in preeclamptic placenta: possible role in regulating activity of the aquoporins-9 (AQP9). Investigator: Dr Alicia E Damiano. Chair of Cell Biology, Department of Biological Sciences, Faculty of Pharmacy and Biochemistry (UBA). Students: Gabriel Colodenco, Martin Sapir.
  http://www.tarkuselp.blogspot.com/
  
  
• Proteomics factors secreted by breast cancer cells and normal breast inhibitory lipid production. Investigator: Dr. Liliana Noemi Grignoli War. Department of Biological Sciences. Faculty of Natural Sciences, UBA-CONICET. Students: Fabiana Durante, Tamara Broitman.
  http://tyf-proyecto08.blogspot.com/
  
  
• neovascularization in a murine model of acute inflammation induced by LPS. Investigator: Eulalia de la Torre. Faculty of Medicine - Uba - Laboratory of Immunopharmacology. Student: Federico Mauas Walach, Paul Kuleff.
  http://finalproyectort.blogspot.com/
  
  
• Study of the Growth Associated Protein (GAP-43), their interaction with Ubicutina and its involvement in cell cycle control NIH3T3 cells stably transfected and transient. Effect of Apo-transferrin in remielización: involvement of the Notch pathway in the differentiation oligodendrioglial. Investigator: Dr. Ana M. Adamo. Biological Chemistry Department of Pathology, Faculty of Pharmacy and Biochemistry, UBA. CONICET. Student: Rodrigo C. Robby Pampin and Mattes.
  http://www.ubiquitination.blogspot.com/

What Retail Store Carries Sephra Chocolate Fondue

Thursday 30 October Thursday 23 October

This week we have a quantification of DNA with electrofotométro, a PCR and purification.
continue with the final draft.

How To Hack A Laptop With A Dongle

In this meeting we developed a PCR and drafted the results for the Final Project.

Diabetes Symptoms In Two-year-olds

Imperfection Perfect Love Artist

LUCIANO- know I think I am, as it were ... "unloved." She is so ... (I cut his friend).

RENATO - other than how to think.

LUCIANO - so I would not but she is just exactly as I thought.

RENATO - Oh, I understand perfectly, when things happen like you thought, is there anything you did not do badly enough.

LUCIANO - I know, but do not know why I did my best to ruin everything.

RENATO - Apparently there was something a few things without realizing it did well.
You must be more careful to avoid making these mistakes, or rather, you have less care, really do not know.

LUCIANO - say that no one is perfect, but she is perfect, and nobody should be perfect, this is the fault of her say that she is a "perfect imperfection."

RENATO - Look on this side, you now have the advantage of being free, when in love only think to blame this horrible crime. And the inevitable attraction of morbidity, not stop thinking about this and you get distracted by all your other goals, if you have them.

LUCIANO - I like to set goals, but not performing. The problem is that now I have to blame for not performing. When this love is one place the best excuses of all kinds.

RENATO- So this is just an excuse and they still love. Right?

LUCIANO - So obviously I am? Because in that case I look for a better to pretend that I'm not.

RENATO - For what purpose?

LUCIANO - To continue loving it, of course.

RENATO - Of course I understand, but if there is a possibility that she loves you, I can think of the ridiculous idea that maybe you should let him know you love her too.

LUCIANO - And what your idea is ridiculous! I hope that there is no mention that possibility. I love to love or be loved, but would hate to happen both at once.

RENATO - I'm sure I'll regret asking this but what I can know why?

LUCIANO - Only once in my life I made the mistake of loving and being loved equally, and discovered that there is nothing as bad as the feeling that one is completely happy. When one feels happy to have it all, so does one feel that it has nothing to do. Not that I have something to do, but at least if you are not completely happy, you have the motivation to find it missing, you have the need to create something new, something artistic and beautiful, to impress the person from whom is in love. But if you find that person in love with you, you no longer need to impress anyone, then comes happiness and happiness limits the imagination and thus artistic creation.

RENATO - I knew that I would regret, I was terribly bored the theme of love, this pretty old fashioned, I'm sure it must have been the first fashion who invented civilization to entertain the middle classes. I also believe that people who talk about love have never experienced it, and those who live never have time to talk about . Yet I agree with you, happy endings so depressed me, are so predictable. I've always preferred the tragedy.

LUCIANO - Living life should be the greatest of tragedies. It is this imperfection that makes life perfect. Like when he's in love with beautiful eyes for which one has never been regarded in the same way. Or when it is committed to someone who loves you intensely, but are unable to close their eyes when you kiss this person. This is to live intensely.

RENATO- But as annoying as it may seem most people yearn for a predictable happy ending which is death. This is the comedy of life. The comfort of many is the hope of knowing that one day will not experience more pain sensations. Instead I would have eternal life and never die. That would be the worst tragedy that a man could have. Living over a thousand years and see how each person you love dies or worse, to see how people die and I loved you flattered. If I had the good fortune to experience something like that, would without doubt the best artist the world has ever known.

LUCIANO- If, as is, you start to bore me with your existential questions.

RENATO- 's because I'm returning to a state of sobriety, and when I'm sober I think clearly it is never good. I need a good liquor, I know a very fine and elegant bar where certain animals know luxury white fur. What do you say we now, perhaps ivory finish pouring liquid before dawn.

LUCIANO- For the particular state in which I feel your invitation I find a complete disrespect of you, so it would be foolish not to accept it. We therefore hope to commit some foolish to cause a scandal. I'm sure she will be furious when he finds out.

Raziel Tovar

October 23, 2008

Ralph Morley Painting

is different how he loves the artist, does not love the same way that an ordinary person does. The artist is not only limited to just love the beauty of art, but also care about love artistically, either vice or virtue. Because the work of an artist is not only creating art, but it is art itself, live art. So when the artist you love someone, does not love the person himself, but he loves the art that manages to look into it. And art is the beauty comes the next question. Does the artist loves physical beauty or the beauty of the soul? We must clarify that physical beauty enhances the beauty of the soul and the beauty of the soul beautifies the body. It is obvious that each artist can tend to the predilection of some of these of these. But the artist who not only loves art, but loves artistically, is responsible through his virtuous abilities to create a balance between these two forms of beauty and turn them into a single object, a symbol that represents the aesthetic beauty in all its manifestations.

20/oct/2008

Milena Velba Cigar Images

The tragedy of being in love

X-am in love with a woman.

L - do not know what is more sad, if being in love, or the fact that it is a woman.

X

I do not see why this has to be sad, I think it's you the one who makes all things is seen as a disgrace.

L-The trouble is that you do not recognize this when you are presented.

X "I have not had the pleasure of meeting.

L "But it you do.

X - "The misfortune, or who I love?

L-No difference. Listen, when you're in love with a woman and not know if it is reciprocated feels anxious and confused, and although he knows that these symptoms desaparcarían face to face with the cause, cringes at the time to act, because at least something sure, you know you have the pleasure of the benefit of the doubt . But if you get an answer final one hand, symptoms may become euphoria and excitement, on the other, there is the possibility of being absolutely nothing. Paradoxically, this last would be the best.

X-doubt completely what I have said.

L-So you've decided to stay with something. That's good to know that I have understood.

X

I still do not understand what's wrong with falling in love with a woman.

L-Veras my dear friend, the tragedy of us is that we are all equal, all of them being so different. All men They can be conquered by the beauty of the other, but women never know they want exactly . That's why the friendship between men is generally stronger than women. Only one man knows how to bring joy to another man. Women are not happy or they do themselves.

X-misogynist For your peculiar way of seeing things, I infer that you try to tell me that I can be happy only having an affair with a man.

L-Solo is meant as suggestions.

X "Sorry but I can not, my choice of subject is contrary to my sex.

L-

same is my case, unfortunately, probably because of our aging culture, but imagine how it would be if no one had a specific object choice, and that could one day fall in love with a woman and another man.

X-It appears that women will have been disappointed enough.

L "I'm not the one who has fallen in love.

X-You are in love with the man who sleeps in your bed.

L-Yes, but even I dare not confess my love, better to get under you're listening.

X-Vanity has the best ears.

L-As good as those of this love, but for the vain all you hear is praise for the love all the comments are insulting the person you love.

Raziel Tovar

October 17, 2008

Watch One Program Tape Another

Interest Attraction or

Scene. A lady is sitting waiting on the table in a restaurant. A waiter is serving the beverages. A young man is coming and sitting with her.

This dusk. Music plays in the background. There are few people around.

- (The girl child). Because you asked me to come to this place.

"I have something to say.

"And I have something to listen to, so tell me, what do you have to say?

"I always I have things to say but does not normally do, always evades the opportunity and just say that I have many things to say.

"Better save yourself the explanations.

"I try to do so, one day I'll see many more of which until now I have.

"She perfectly what you mean, otherwise it would not be here.

"I had no idea what I will tell you, if I had known, I assure you was as far as possible from here. Unfortunately here I am, and the truth is that I like very much.

- Unfortunately for you or me?

"I think for both.

"I know.

"I also knew you knew.

- Why do not you tell me before?

"If I could explain it, would not be having this conversation.

"Unfortunately we're having, so I demand a response.

"I have no answer, just lots of questions.

"I persuaded your answer, but I need a good argument to convince me because you liked, so please continue.

- Continue? And when I stopped?

"Excuse me, I hear.

"I'm glad you listen.

-From flamenco music, to rock, and pop and other genres.

- What other genres?

-The mostly male, so we keep talking yet.

"Sorry did not want to bother you.

"Do not worry I'm fine sitting here comfortable.

"You know, I know people beautiful, intelligent and some other arts. You're the only beautiful, intelligent and artistic people I know.

- And if he lacked some of those qualities?

- Well, I need to pay close attention to what I'm going to say. There are people that I find interesting because I like, but I like you because you're interesting.

What is the difference between them?

"In the first is anyone who could be beautiful, therefore attracts me, what makes me think it's interesting, but eventually I realized that I let go, then discover how boring it can be that person. In the second case it is someone that is really interesting, someone you can talk of an indefinite variety of subjects, this makes him a beautiful person and that's when I like. This is the argument that I have to convince. Now tell me what you think about all this.

"I still have not told me everything, you lack the most important, ie the most important proposition.

- Who's talking about a proposition?

"I just do me, but are you the one to make it.

"Sorry, these confused, I just wanted you to say I like you because you are interesting, not interest me because I like you.

- Ahem! (cough). Now if I feel uncomfortable.

"Maybe you should change positions.

- And what should I take?

-La that contains more alcohol of course.

"No volume.

"I'll make for you.

"Then feel disappointed, maybe angry.

"I feel successful. (He moves a bit and straighten your back).

"I have to go, I've been waiting but you came too late.

"Excuse me, I can not really remember when it comes, but my parents say it was at noon on April 1.

"If you had come a few months earlier would have been very good.

- Am I wrong?

"You could have done better. (Gets up and leaves.)

- (To waiter). You can pick these drinks and bring me another.

- Are you sure sir? Their drinks are still in the middle.

- If there is no problem, I like leaving things half and start over, I like to feel when something is about to end.

Raziel Tovar

October 17, 2008

Jc Penney Salon Products

Thursday, October 16 Thursday, 2 October

At this meeting we mutations on the results of DNA sequencing. He later finished writing "Materials and Methods" and draft conclusions.

Balance Laptop 557s Driver

In this meeting a second PCR, a second purification and finally sequenced. We continue with the writing of "Materials and methods."

How To Get Basic Cable With Indoor Antenna

In this meeting electrophoresis and PCR.
started writing "Materials and Methods" for the Final Project.

Moonshine Acrostic Poems

Thursday, 25 September Thursday 18 September Thursday, 4 September

At the Academy we learned of a University that was being carried out on the ground floor of the establishment. We concur with the statement of SAF (antiphospholipid syndrome).
Upon returning to the laboratory perform electrophoresis (CSGE) and PCR.

Epididymitis How Long Does It Last

OF DESIRE AND LOVE

Love is a disguised habit of virtue, as one thinks is happily in love until a cause of jealousy feel a visceral hatred for the selfish love that had to the person, is when one realizes that one has attachment to the object of his affection. Is there anything more absurd than jealousy?

not mean that this love is that it has become an addiction, a nasty habit, a vice too human.

Me I love but whether or not your name, if not his vices that hide his voice. I'm attracted to both their perfidious actions, their hypocrisy, their profligacy. Sometimes the beauty is hidden behind masks to avoid being eaten dire. You can find beauty in the most vulgar.

The boy is in love, now forget, if you do not want to reappear human traits in his face and drown in the most absurd feelings. The child was entrusted, and he thought I will have to happen, but it is too late, when the blood boils consciousness evaporates and the lessons are forgotten and there has started to return.

release impatiently wanted, but still attached to the body, not by foreign chains but the chains of my own passions. The enemy took possession of my will and made me shackles preventing any movement. Because of the desire born of lust and lust born of habit, a habit that I can not resist. Has created in me a kind of needs whose links attached to one another kept me in a cruel and latent slavery.

Night comes, blood begins to boil, a Sucubus appears, his face is your name. Then Sucubus Take my hand, puts about desire. Begins to move restlessly, until they can do more, is poured around thick ivory. It seems that the sucubus is gone, but has quietly hidden.

Raziel Tovar

September 13, 2008

Mrs. Lovett Costume With A Ha

In this meeting we developed a PCR. While waiting for the thermal cycler to amplify end we made a new DNA extraction method described above.

Dog Fur Discoloration Stomach

INTRODUCTION

History
von Willebrand disease was first described in 1926 by physicist Eric Adolf von Willebrand disease. His first patient was Hjördis, a five year old girl who suffered from recurrent bleeding lips, nose and ankles. It was not the first case in her family, four of his brothers had died of uncontrolled bleeding early. At age 13 she died at menarche. [1] Dr. von Willebrand
distinguished this case of hemophilia after realizing that the injuries caused by the VWD differed from those caused by haemophilia because it is the first external bleeding and internal bleeding in the second case. When analyzing the bleeding time and capillary fragility test scored abnormal values. In turn, studies of platelet count and clotting time results were within the range considered normal, which would not have happened if it had been a case of hemophilia. That is why the doctor concluded that it was modified morphological changes of platelet function and called it "pseudohemofilia."
In 1928, Dr. George Minot of Boston described five cases in which the bleeding time was high but contrary to that obtained by Dr von Willebrand, capillary fragility test was negative. Continuing research
was assigned to the disease the name "vascular hemophilia" because it is a disorder of blood vessels. In the 1950's it was discovered that hemophilia is sex-linked so it affects only men (women are carriers but do not have the disease). This was known a new difference between the two diseases. Also noticed that members of a family of hemophiliacs had similarly low levels of FVIII, while a family who suffered from von Willebrand disease, the values \u200b\u200bof this factor varied.
At that time he began to use the plasma transfusion. We performed a transfusion of a patient with hemophilia A in a VWD, causing a slow increase of FVIII, which remained a few days and then decline.

However, the plasma transfusion in reverse (a hemophiliac VWD) FVIII values \u200b\u200bremained the same. It was discovered that in cases of VWD was in a new factor deficiency could be restored by normal or haemophilic plasma.
In the 1960's found that ristocetin, an antibiotic, stimulated platelet aggregation in normal subjects or hemophiliacs but not in people with VWD. If adding platelet-poor plasma from a normal or hemophilic VWD a patient with a platelet-rich plasma, the antibiotic worked. So the discovery of a new test to detect the VWF, which was not yet known as such.
When they semi-purified FVIII injected a group of rabbits, they produced an antibody that recognizes a substance found in people suffering from hemophilia A. This substance was called "antigen factor VIII (FVII: Ag). Later it was discovered that two different factors: the factor VIII and VWF, which could be separated.
In 1985, VWF was cloned and sequenced for the first time and was able to study the relationship between their structure and function. [2]

Physiology of hemostasis
Upon endothelial injury starts primary hemostasis: platelets adhere to subendothelial structures, interacting with specific receptors and exposing their receptors for VWF and fibrinogen, this process leads to platelet adhesion and aggregation and release the contents of their granules (a and dense) with platelet plug formation, in turn activates the coagulation cascade, which together with activated platelets produce coagulation activation.
in blood clotting plasma proteins involved many known as "factors" (F), which circulate as zymogens which, when activated have enzymatic activity, and in many cases serinoproteasas and cofactors of coagulation. This process also presents a chain reaction leading to the amplification process, called "coagulation cascade" and self-limiting reactions that operation (natural anticoagulants).
The process of extrinsic pathway is initiated by tissue factor (TF) exposed to circulating FVII to form an activating complex to FVIIa. This complex, FT-VIIa, activates FX.
The intrinsic pathway involves the activation of FXII to FXII, which activates FXI to FXIa happens. This, in turn, activates FIX to FIXa happens. The FIXa forms a complex with FVIII activator, platelet-derived phospholipids and calcium. This complex acts on the FX to activate, combining both approaches. FXa binds to FVa and acts on prothrombin (FII), producing thrombin (FIIa). Thrombin activates FV and FVIII, generating FVa and FVIII and fibrinogen producing fibrin, which strengthens the platelet plug to form a stable clot by the support of fibrin (Figure 1).

This stabilizing action is carried out by FXIII. This knowledge in haemostasis have been acquired from the analysis of congenital deficiencies of various clotting factors that are associated with a hemorrhagic syndrome florida. Hemophilia A is given by a deficiency of FVIII: C, Hemophilia B FIX deficiency (described by the Argentine Alfredo Pavlovsky) and the present one, the VWD by VWF deficit with initial contributions of Dr core group Pavlovsky since 1957, first director of the Instituto de Investigaciones Hematologic "Mariano R Castex", where we develop this work. [3]

Synthesis and structure of
VWF VWF is a multimeric glycoprotein. The number of subunits varies from one molecule to another. Each subunit contends two thousand and fifty to twenty amino acids and carbohydrate side chains carbon. The units are joined in pairs by disulfide bonds, forming dimers of 500 kD.
The VWF gene is 180 kb and contains fifty-two exons. It is located on the short arm of chromosome 12. The primary
RNA translation gives the pre-pro-VWF, a polypeptide twenty-eight hundred thirteen amino acids. The newly synthesized protein consists of a signal peptide of twenty amino acids, the peptide of seven hundred forty-one amino acids and the mature subunit, two thousand fifty amino acids. [4] The protein is synthesized in endothelial cells and megakaryocytes. From there it is released into the subendothelium and plasma. Is deposited in the granules to platelets, in Weibel-Palade bodies of endothelial cells in the subendothelium. [5] (Figure 2)
The pre-pro-VWF becomes pro-VWF to get the signal peptide. Then glycosylated with simple sugars for transport to the Golgi apparatus. The pro-VWF monomers associate to form dimers. The noncovalent association of regions of propeptides promotes multimerization through disulfide bonds in the D3 domain of the amino terminal. Once completed the multimerization, the VWF is stored in storage organelles. In endothelial cells VWF stored in Weibel-Palade bodies. In megakaryocytes and platelets are stored in a -Granules. Propeptide dimers are removed before the secretion of VWF. This peptide was originally known as "von Willebrand antigen II." There are two secretory pathways: one constitutive (related to the synthesis) and a regulated pathway that involves the release of VWF-mediated secretagogues (activators of secretion). The VWF in megakaryocytes and platelets derived from the regulated pathway. The VWF circulating in plasma is of endothelial (constitutive pathway). [4]
VWF consists of a series of homologous segments (domains), each of which is repeated two to four times [6]. There are 3 repetitions of A, 3 B, 2 C and 4 D. Link the various functions of VWF appears to be localized in these domains. The site of interaction with GPIb is located in the A1 domain [7]. Also, within such domain, there is a binding site for collagen and a binding site for heparin [8]. The binding domain for factor VIII (FVIII) has been located in the fragment comprising 272 aa in the N-terminal region, corresponding to the domains D 'and part of D3 [9]. In the A2 domain is the ultimate proteolytic site (Figure 3).


The A3 domain is another binding site for collagen [10] and it has been suggested that this is the physiological site of interaction with collagen [11]. The tetrapeptide RGDS, which mediates the binding of VWF to the complex IIBB 3 (GPIIb-IIIa) to activated platelets, is located near the C-terminal C2 domain [12].

function
VWF VWF has three main functions: on the one hand it promotes the adhesion of platelets to subendothelial structures at the site of vascular injury. Here the VWF binds to collagen exposed through the A3 domain, this causes a conformational change in the VWF A1 domain that exposes the binding sites of GP Ib on platelets. On the other hand protects FVIII from inactivation and rapid catabolism, by training a noncovalent complex with it, through the D'-D3 domains, FVIII binding site. It also promotes platelet-platelet interaction by binding to platelet GP Ib and GP IIb-IIIa. This link not only depends on the presence of VWF and its quality, but also of other adhesive proteins such as fibronectin, laminin, thrombospondin, and different types of collagen. [1]

Classification of von Willebrand disease
Von Willebrand disease is caused by a deficiency of VWF cualitatitva or quantitative, which prevents platelet plug formation. VWD is currently
the most common bleeding disorder, with prevalence ranging between 0.8 and 1.3% of the population.
has been subdivided into two major categories reflecting the pathophysiology of the disease: quantitative and qualitative variants, types 1 and 3 are quantitative variants, refer respectively to the total or partial reduction of VWF whereas type 2 refers to deficiencies qualitative. Sadler [13] suggested in the revised classification introduced in 1994, subdivided into 4 type 2 variants (2 A, 2B, 2M, 2N or Normandy) according to specific details of the phenotype.

quantitative VWF defect:
• Type 1: partial quantitative deficiency of VWF in plasma and / or platelets.
• Type 3: complete deficiency of VWF in plasma and platelets.
The most common form of the disease is type 1 (70-80% of cases), characterized by comparatively low levels of FVIII: C, VWF antigen (VWF: Ag) and ristocetin cofactor activity ( VWF: RCo), produced by a decrease in the synthesis, with normal multimeric composition. The decrease in FVIII: C in this case is secondary to reduced VWF. The platelet VWF is present but may be decreased or normal.
Option 3 is the least common, but clinical symptoms presented severe. Represents 5-10% of the cases studied. It is characterized by undetectable levels of VWF: Ag and VWF: RCo with greatly reduced levels of FVIII: C.

Influence of blood group on plasma VWF levels
normal individuals were described with group 0 have lower levels of FVIII: C and / or VWF lower than those with other blood types. Although no one knows the reasons for this, the physiological basis of these differences are probably related to the type or amount of glycosylation of VWF, leading to a shortened survival itself. Gill et al (27) assessed the prevalence of each blood in patients with Group 0, finding that 77% of patients with type 1 had group 0, which is higher than the prevalence of this group in the general population. No significant differences in the prevalence of group 0 among patients with type 2 and 3.

qualitative VWF deficiency (type 2):
With decrease in high molecular weight multimers:
• 2A: Decreased affinity for platelet GP Ib
• 2B: Increased affinity for platelet GP Ib.
with normal multimeric structure:
• 2M: Decreased affinity for platelet GP Ib.
• 2N: marked decrease in affinity for FVIII.
type 2A is characterized by a qualitative change, which would be much diminished or absent multimers of high and intermediate molecular weight, both in plasma and platelets in plasma are decreased or absent VWF: RCo, with slightly reduced or normal levels of VWF: Ag and FVIII : C. 2B
type plasma has the same pattern, with a decrease of large multimers in plasma, but present in platelets. Multimeric structure in this case has a greater affinity for GPIb. This phenomenon can cause thrombocytopenia. In this case, the differential diagnosis of type 2B capacity to agglutinate platelets in the presence of low doses of ristocetin (0.3 ug / mL).
The presents type 2M VWF: RCo greatly diminished or absent levels of VWF: Ag and FVIII: C slightly decreased or normal, with normal multimeric pattern.
2N variant is characterized by an impaired ability to bind to the FVIII: C, with a consequent decrease in its half-life and low plasma levels of FVIII: C and VWF: Ag and VWF: RCo normal.
recently Lethagen reported that a significant number of patients diagnosed as type 1, mutations that would require to be reclassified as type 2. It further suggests that some patients would be helped at the clinic for the DDAVP [14]. Castamir described a lack of association between genotypes, history of bleeding and VWF: RCo in many families diagnosed with type 1 mild. This leads to consider that therapeutic decisions could not be based solely on phenotypic variants. [15]

Alternative 2N
This subtype that is caused by inherited recessive mutations in the domains D 'and part of the D3, that modulates the binding site of VWF to FVIII. Patients may be homozygous for substitution mutations or compound heterozygous for two different mutations. They may also have mutations in the binding site or a null mutation. About twenty mutations have been described. Most of them are located between exons 18 and 20, affecting the FVIII binding domain. Other mutations have been described in exons 17 and 21 to 27 who are outside the FVIII binding site and are also responsible for the decrease in binding capacity between VWF and FVIII. The R854Q mutation is the most frequently reported.

Bibliography

[1] Von Willebrand disease update: diagnostic dilemmas and Treatment . Bolton-Maggs PHB, D. Lillicrap, J. Goudemand, E. Berntorp. 2008

[2] Von Willebrand disease - and introductory discussion for young physicians. Carol K. Kasper, Los Angeles. October 2005

[3] Foundations for the practical use in the laboratory of haemostasis.

CAHT

Group [4] New perspectives on VWF functions in hemostasis and thrombosis. Loredana Mendolicchio Grazia, M. Zaveri Ruggeri. 2005

[5] Von Willebrand disease. Wagner. 1990

[6] Bonthron et al, 1986, Verweij et al, 1986; INLO Shelton et al, 1987

[7] Mohri et al, 1988; Mohri et al, 1989, Vicente et al, 1990; Sugimoto et al, 1991

[8] Pareti et al, 1986; Roth et al, 1986; Fujimura et al, 1987; Mohri et al, 1989

[9] Foster et al, 1987; Takahashi et al, 1987; Bahou et al, 1989

[10] Roth et al, 1986; Kalafatis et al, 1987

[11] Cruz et al, 1995; Lankhof et al, 1996

[12] Beacham et al, 1992

[13] Sadler JE.1994

[14] Lethagen S, et al, 1998

[15] Castaman G et al, 1999

Whats A Good Phrase For A Soccer Themed Party

Today's meeting is dedicated to find the information we needed and finish writing the introduction to our final project.

Antique English Baby Prams

Thursday, August 14 Thursday

This week we reveal the resulting gel electrophoresis conducted last week. First we fix it with ethanol (300ml), acetic acid (100ml) and water (to fill a liter), leaving the gel for 1 hour. The dyed with silver nitrate (0.5 g per 0.5 l of solution prepared) for 1 hour. Eventually reveal. To this, add a solution of 21.6 ml of formaldehyde (0.4%), 30g NaOH (1.5%) and free water (up to complete the 2l). After this step we see the bands obtained.

Time Period To Send Sympathy Card

Thursday July 24 July 17 July 10

This week we electrophoresis of DNAs obtained from the PCR to last week. We prepare Cuba's 20 x 40, the gel (acrylamide, ethylene glycol, tristaurina EDTA buffer, free water, ammonium persulfate and fear), then sow the samples (DNAs results of the 3 types of different DNA extraction, 2 normal heteroduplex between patient and normal) and let it run 24 hours. Next week I will reveal and analyze the results.

Why Is An Enlarged Heart Bad?

Thursday

At this meeting we did PCR on blood stored in the mini-cards last week. After that Adrian showed us the auditorium of the Academy, which has books several centuries ago in display cases. Finally we were writing the introduction to this work.

today Photos: http://www.slide.com/r/pIseiEII0j9vrcs6doj5n2HfzCM_zmMY?previous_view=mscd_embedded_url&view=original

Printable Green House Plans

Thursday July 3 Thursday, 26 June

This week we returned to extract DNA and test the "Mini-cards" that was left to Adrian last week to try. The mini-cards are some cards to store blood samples without freezing in pipes. For this, a few microliters of blood placed within each circle drawn on the board and allowed to dry for a while. There are different sizes of cards and each requires a different time to dry. Furthermore, some have only one large circle, while others have four circles, so you can keep blood from different patients. They also have a space for labeling. Next week we will make a PCR using blood stored in this way.
Today also saw the differences in DNA sequencing according to the amount of magnesium is placed in the PCR.

today Photos: http://www.slide.com/r/Xs6wkw4P1T8dyXDFTUeqN2KbDWnu35xs?previous_view=mscd_embedded_url&view=original

Whats Anjeer In English

Today we returned to do PCR.
saw the differences in results when using magnesium (left) or omitted to use (right).
While waiting for the thermocycler finished work, seek information in folders and Adriana gave us a website recommended by her: www.ncbi.nlm.nih.gov / PubMed

Jack In The Box Mascot Actor

At this meeting we electrophoresis. Adriana first showed us how to prepare plates and prepared the gel. To use a gel buffer (tristaurinaEDTA) piperazine acrylamide, ethylene glycol, formamide, distilled water, persulfate and fear.
The pipette we use for acrylamide should be dismissed because the chemical (uncured) is very toxic.
We had to do twice the gel because it gelled.
When the race was ready we took her to UV. Adriana
showed us copies of gels and some gels that were saved and we get information to photocopy.

today Photos: http://www.slide.com/r/dK0Ktq5E6z-ZwTjUdp-hN3zVFdFyHwiq?previous_view=mscd_embedded_url&view=original

Carribean Themed Prom

Thursday, 19 June Thursday 12 June Thursday, 5 June

PCR made at this meeting, which aims to amplify with specific primers a DNA fragment of interest.
to the mix that we add to the DNA samples we use water, buffer, dNTP, Mg, primers and TaqPol.
must meet certain conditions:
• The first should be 18 to 24 pairs of bases and can not have Police, polygamists, poly or political.
• The temperature of annealing (hybridization) can not be less than 50 º C and should be about 5 ° C below the melting temperature.
· T. Melting = 4 (G + C) + 2 (A + T). Should be given between 40 and 60%.

also did DNA extractions.

today Photos: http://www.slide.com/r/hC4UVSGL0j-zkSzfLnulSrSSEI9Iar8N?previous_view=mscd_embedded_url&view=original

What Can You Wear With A Halter

This week we started working with patients suffering from Von Willebrand disease type 2N. As in the past encounter raw blood DNA extracted using the same method. Due to time constraints we had to conclude the pilot to continue it in this part next week.

today Photos: http://www.slide.com/r/-J1Ctitc4D-zTFtNavZDg1CNXgAiAwYb?previous_view=mscd_embedded_url&view=original

Tooth Extract Now Swollen

In this third meeting we started working, using a standard blood sample (without disease). To teach the technique, Adriana preparing a tube and we repeated it in triplicate.

Part One:
eppendorf tubes put in 500 ul of lysis solution. Add 300 ul of whole blood, taking care not to be formed bubbles. Propipeta mix for evacuation.
add 100 ul of 33% sucrose solution at the base of each tube without mixing the phases. We plugged the tubes and centrifuged at 13500 rpm for 2 minutes.
discarded the supernatant taking care not to remove the pellets.
We wash with 300 ul of PBS, mixing again for evacuation pipette.
add 100 ul of 11% sucrose solution at the base of each tube without mixing the phases. We plugged and re-centrifuge at 13500 rpm for 2 minutes. Again
discard the supernatant taking care not to remove the pellets.
add 75 ul of NaOH and vortex.
incubated in the thermocycler at 95 ° C for 14 minutes and 30 ° C for 1 minute. Centifugamos
briefly to lower condensation on the walls of the tube (use the "press").
neutralized with 10.5 ul of Tris / HCl and centrifuged 4 minutes at 14000 rpm.
DNA is found in the supernatant.
* Note: Each time a tip comes in contact with the sample should be excluded to avoid contaminating the solutions. Since we were using blood from one person, we put the necessary solution to each tube (without touching the sample) and after evacuation were mixing by pipette. When working with samples of different people we are going to use a tip for each sample.

Part Two: We
DNA to the third floor of the Academy, where was the spectrophotometer. We use a quartz cell plastic because the cells do not efficiently transmit ultraviolet light. We measured the absorbance at 230 nm, 260 nm (maximum absorption) and 280 nm.

At the conclusion of the pilot, Dr. Woods continued with the theoretical explanation about what they will do next week (PCR). Then he showed us the program Oligo, used to design primers that can identify potential problems and disadvantages of the design (the union of the chain, annealing temperature of melting, content G and C bases) for the best first time possible to make it.

today Photos: http://www.slide.com/r/IAbJpoLCwz-wsZcy8VSv8bYoiDEOg0_P?previous_view=mscd_embedded_url&view=original

Motor Knex Instructions

Thursday 29 May Thursday 22 May Thursday

In this second meeting the doctor continued with the theoretical explanation of Von Willebrand disease. He showed us the different types of tests done for them: bleeding time, ELISA (photo), etc.

By Adriana scheme explained how hemophilia is inherited; when one is a carrier (only females), when one has the disease (men only) and cases of healthy men.
Finally we saw the different types of VWD (type 1, type 2A, 2B, 2M, 2N and type 3), what distinguishes them and what tests are implemented for a diagnosis.

All these cases were exemplified to see what range of data the patient has von Willebrand disease.

How To Know If You Have Stomach Bleeding

May 15

Today we started the project. At this first meeting we knew the place: the library, the area of \u200b\u200bpatient care, laboratories, address ...
Then Dr. Adriana Woods, a researcher with whom we work throughout the year, taught us about Von Willebrand disease (VWD) and hemophilia. We learned the coagulation cascade, laboratory methods to determine the qualitative and quantitative deficiencies of the various factors and interactions of Von Willebrand factor (VWF) to platelets, factor VIII and subendothelial tissue.

today Photos: http://www.slide.com/r/kkyBq6nQ2j9kdVRyYkXMTANMgf1Bz1E3?previous_view=mscd_embedded_url&view=original

Quotes To Put In Wedding Invitation

Curriculum Dr. Adriana Woods

CURRICULUM VITAE

ADRIANA INES WOODS






PERSONAL DATA NAME: Adriana Inés Woods

PLACE AND DATE OF BIRTH: Maciel (Santa Fe)
05/31/1953
DOCUMENT: ID: 10,761,901
CI: 11,265,898 (Federal Police)

MARITAL STATUS: Married

ADDRESS: 2367 7th Lacroze Federico B. Federal Capital. (CP: 1426)

PHONE: 4-772-2540

TITLE: Biochemistry (Universidad Nacional de Córdoba) 11/06/1977

CURRENT POSITION: Part of the Support Staff Career of CONICET.
Category: Home Professional.

WORKPLACE: Department of Haemostasis and Thrombosis, Hematological Research Institute 'Mariano R Castex ", National Academy of Medicine.
Pacheco de Melo 3081, Buenos Aires.


WORK HISTORY IN THE CONICET

- Part of the Career of CONICET Support Staff.

categories: professional technical assistant from 03/10/1983 until 31/07/1991.
leading professional technical
from 01/08/1991 to present. WORK HISTORY UNDERGRADUATE


- Practitioner honorary Laboratory Neonatology, Provincial Maternity Hospital, Cordoba, the 06/18/1973 to 31/03/1975.

- Practitioner honorary Central Laboratory, Hospital Nacional de Clínicas "Dr. Peter Vella, a city of Cordoba, from 08/04/1975 to 02/01/1976.

- Practitioner lower Central Laboratory, Hospital Nacional de Clínicas "Dr. Peter Vella, Cordoba DM by Resolution No. 1904 of the Medical Faculty of the UNC, the 01/02/1976 to 31-12 - 76.

- Practitioner greater Central Laboratory, Hospital Nacional de Clínicas "Dr. Peter Vella, a city of Cordoba by Resolution No. of the School of Chemistry, UNC, from 01/01/1977 to 06/30/1977.

- Guard Officer of the Council of Central Laboratory, the National Clinical Hospital "Dr. Peter Vella, a city of Cordoba, from 03/01/1977 to 07/31/1977.

- Practitioner's largest Clinical Laboratory, Department of Clinical Ophthalmology, National Clinical Hospital "Dr. Peter Vella, a city of Cordoba, from 01/02/1977 to 31/10/1977.

UPDATE COURSE GRADE PRE

- Immune Response. Biochemistry Association of Cordoba, in September. 1975.

- Hematology. School of Medical Assistants. Faculty of Medical Sciences, UNC, oct. 1975.

- Topics of Parasitology and Mycology. Practitioners Ateneo Biochemistry. Academic Unit of Medicine, Hospital San Roque, Córdoba, 17 to 21/11/1975.

- Endocrine Laboratory in Obstetrics. Biochemistry Association of Cordoba, and 1/2-9-76 24/25-9-76.

- Sixth Form of hematology, immunology and laboratory. Hemotherapy and Blood Institute. National Clinical Hospital. UNC 11 to 16/10/1976.

- Diabetes. UniMediCor, UNC, 24 to 29/10/1976.

- Chagas Mazza. Biochemistry Association of Cordoba 5 / 6 and 12/13-8-77.

- Renal Transplant and Hemodialysis. Medical Center Kidney Disease and Hypertension.
Córdoba, 08/20/1977.

- Hematology, Immunohematology and Hemotherapy. Society of Hematology and
Hemotherapy of Córdoba. from 22 to 26/08/1977.

- Roundtable on "Behavior of Medicine, Department of Medical Education
Roemmers Laboratories. Cordoba, in September. 1977.

- XIV Course immunopathology. Chair and Institute of Allergy and Immunopathology,
National Hospital de Clinicas, Córdoba. from 08/07/1977 to 09/10/1977.

- Assistant to the Conference and I VIII Argentine Congress of Mycology. Córdoba. from 4 to 8/10/1977.

- Mycological Diagnosis and Immune. Conferences and I VIII Argentine Congress of Mycology. Cordoba
5 to 10/07/1977. GRANTS COMPETITIONS




- FECIC (Foundation Educational, Scientific and Cultural Organization) of 01/05/1978 to 05/01/1980.

Labour Issues:
a) Comparison of a human brain cephalin and commercial phospholipid in the implementation of Activated Partial Thromboplastin Time.
b) Standardization of the technique of Platelet Factor 3 availability.
c) Controls on Antithrombotic Therapy. Presented at the Sociedad Argentina de Investigación Clínica, Mar del Plata, November 1979.
d) Detection Technique platelet microaggregates: an attempt at clinical application.

Workplace: Department of Haemostasis and Thrombosis, Hematological Research Institute, National Academy of Medicine.

- CONICET, 04/01/1980 to 01/04/1982.

Category: Initiation. Theme

work: Participation of platelets in the fibrinolytic system.

Scholarship Director: Dr Maria Angela Lazzari Lopez.

Workplace: Department of Haemostasis and Thrombosis, Hematological Research Institute 'Mariano R. Castex ", National Academy of Medicine. Buenos Aires.
PARTICIPATION IN CONFERENCES AND SCIENTIFIC MEETINGS

- Days of arterial and venous thrombosis. Latin American Cooperative Group
Hemostasis and Thrombosis (CLAHT). Bs As, 18/20-4-79.

- XXIV Meeting of the Society for Research Argentina Clinic. Mar del Plata, November 1979.

- Sixth Latin American Congress of Hemostasis and Thrombosis.
Latin American Cooperative Group of Haemostasis and Thrombosis. Buenos Aires, October 1980.

- Week Haematology Argentine-British. Hematologic Research Institute "
Mariano R. Castex", National Academy of Medicine. Buenos Aires, September 1980.

- VII Ibero-American Meeting of Haemostasis and Thrombosis, San Jose, Costa Rica, July 1981.

- VII International Congress on Thrombosis and Haemostasis. Toronto (Ontario), Canada, July 1981.

- XXVI Scientific Meeting of the Sociedad Argentina de Investigación Clínica. Mar del Plata, November 1981.

- Buenos Aires '81 Symposium. "Lipids, Platelets and Thrombosis."
Latin American Cooperative Group of Haemostasis and Thrombosis. Bs As, 16/18-11-81.

- German Week Haematology. Buenos Aires, October 1982.

- Buenos Aires '83 Symposium. "Antithrombotic Therapy." Latin American Cooperative Group
Haemostasis and Thrombosis. Buenos Aires, September 1983.

- VIII Latin American Congress of Hemostasis and Thrombosis. VIII Workshop Latin American Cooperative Group
Hemostasis and Thrombosis. Montevideo, Uruguay, in September 1983.

- XXVIII Scientific Meeting of the Sociedad Argentina de Investigación Clínica. Mar del Plata, November 1983.

- Buenos Aires '84 Symposium. "Wall Vascular-Platelet Interaction."
Latin American Cooperative Group of Haemostasis and Thrombosis. Buenos Aires, August 1984.

- XX Congress of the International Society of Hematology. Bs As, 1/7-9-84.

- Week Haematology Scandinavia. Buenos Aires, July 1985.

- Buenos Aires '85 Symposium. "Adhesiveness and platelet aggregation, and Clinical Pharmacology." Latin American Cooperative Group
Haemostasis and Thrombosis. Buenos Aires, September 1985.

- I Scientific Meeting 1986. Argentinean Cooperative Group of Haemostasis and Thrombosis.
Topic: Fibrinolysis. Bs As, 03.29.1986.

- II Meeting Scientific, 1986. Argentinean Cooperative Group of Haemostasis and Thrombosis.
Topic: von Willebrand disease. Bs As, 06.26.1986.

- Buenos Aires '86 Symposium. "Thrombolytic Therapy: Tissue Plasminogen Activator." Latin American Cooperative Group
Haemostasis and Thrombosis. Buenos Aires, September 1986.

- III Scientific Meeting 1986. Argentinean Cooperative Group of Haemostasis and Thrombosis.
Topic: Experiences and methodological applications of Group members in different
CAHT International Centers in 1986. Buenos Aires, October 1986.

- XI Congress of the Latin American Association of Pharmacology. II Congress of the American
Clinical Pharmacology and Therapeutics. Bs As, 24/29-11-86.

- I Scientific Meeting 1987. Argentinean Cooperative Group of Haemostasis and Thrombosis.
Topic: Use of blood in patients with congenital and acquired disorders of hemostasis.
Indication and treatment regimens. Bs As, 06.05.1987.

- International Congress on Thrombosis and Haemostasis. Brussels, Belgium, 6/10-7-87.

- II Scientific Meeting 1987. Argentinean Cooperative Group of Haemostasis and Thrombosis.
Topic: Methods of diagnosis and treatment goals in thrombosis. Bs As, 31.07.1987.

- III Scientific Meeting 1987. Group Argentine cooperative Haemostasis and Thrombosis.
Theme: Disorders of hemostasis in malignant diseases. Bs As, 11.09.1987.

- Buenos Aires '87 Symposium. "Physiology and treatment of thrombosis." Latin American Cooperative Group
Haemostasis and Thrombosis. Bs As, 14/16-9-87.

- IV Scientific Meeting 1987. Argentinean Cooperative Group of Haemostasis and Thrombosis.
Topic: Antithrombotic therapy in various medical conditions. Cordoba, 11/27/1987.

- I International Symposium on Thrombosis. Argentinean Cooperative Group of Haemostasis and Thrombosis.
Bs As, 11/13-4-88.

- Satellite Meeting of the First International Symposium Thrombosis. Argentinean Cooperative Group
Haemostasis and Thrombosis. Mendoza, 14/15-4-88.

- Franco-Argentine Symposium of Hematology. Bs As, 21/22-4-88.

- Medical Conference on Thrombosis and Anticoagulation. Roemmers Foundation. Bs As, 13/14-6-88.

- II Scientific Meeting 1988. Argentinean Cooperative Group of Haemostasis and Thrombosis. Topic:
Desmopressin (DDAVP) in the treatment of disorders of hemostasis in
different pathologies. Bs As, 07.01.1988.

- Buenos Aires '88 Symposium. "Endothelial cells and thrombosis."
Latin American Cooperative Group of Haemostasis and Thrombosis. Bs As, 14/16-9-88.

- III Scientific Meeting 1988. Argentinean Cooperative Group of Haemostasis and Thrombosis. Topic:
antiphospholipid Inhibitors, clinical aspects, diagnosis and treatment. Bs As, 28.11.1988.

- II Educational Symposium on Antithrombotic Prophylaxis and Therapy. II Scientific Meeting of the Argentinean Cooperative Group
Haemostasis and Thrombosis. Bs As, 4/5-4-89.

- Satellite Meeting of the Second Symposium on Prophylaxis and Therapy Education Antithrombotic; Argentinean Cooperative Group
Haemostasis and Thrombosis. Cordoba, 07/04/1989.

- International Symposium I Argentinean Cooperative Group of Thrombosis and Haemostasis and
Cooperative Group Latin American Hemostasis and Thrombosis. Argentina Society for the Study of Thrombosis
. Bs As, 29.05.1989.

- III Scientific Meeting 1989. Argentinean Cooperative Group of Haemostasis and Thrombosis.
"Causes of congenital thrombotic disease." Bs As, 04.08.1989.

- III International Symposium Argentinean Cooperative Group of Haemostasis and Thrombosis. "
Trends in treatment of thrombotic disorders." Bs As, 9/11-5-90.

- Buenos Aires '90 Symposium. "Atherogenesis and thrombogenesis, Physiology and Treatment." Latin American Cooperative Group
Haemostasis and Thrombosis. Bs As, 5/7-9-90.

- II Meeting Science 1990. Argentinean Cooperative Group of Haemostasis and Thrombosis.
"Participation of leukocytes in the regulation of hemostasis. Bs As, 10.18.1990.

- III Scientific Meeting 1990. Argentinean Cooperative Group of Haemostasis and Thrombosis.
"Modulators endothelial and thrombosis." Bs As, 12.17.1990.

- IV International Symposium Argentinean Cooperative Group Haemostasis and Thrombosis. "New therapeutic perspectives
thrombosis." Bs As, 9/11-4-91.

- II Scientific Meeting 1991. Argentinean Cooperative Group of Haemostasis and Thrombosis.
"Thrombosis and Haemostasis. Bs As, 06.14.1991.
- Conference "Thrombosis Factors and Growth and Proliferation of Smooth Muscle Cells
in atherosclerosis and coronary restenosis. "Argentinean Cooperative Group
Hemostasis and Thrombosis, Bs As, 16.09.1991.

- Symposium:" Endothelium, coagulation and thrombosis. Determinants in the development of atheromatous lesions
and restenosis. Atheroma regression. "
Argentinean Cooperative Group Haemostasis and Thrombosis, Bs As, 09.20.1991.

- Measurement of eicosanoids by EIA. Argentino Cooperative Group of Hemostasis and Thrombosis.
Bs As, 11.10.1991 .

- III Scientific Meeting 1991. Argentinean Cooperative Group Haemostasis and Thrombosis.
Topic: Thrombosis in Neurology. "Bs As, 11.06.1991.

- XII International Congress of the Latin American Cooperative Group of Haemostasis and Thrombosis.
Buenos Aires, from 18 to 11/22/1991.

- I Scientific Meeting of 1992 . Argentinean Cooperative Group Haemostasis and Thrombosis.
Theme: "Coagulation and Thrombosis in Obstetrics." Bs As, 04.10.1992.

- V International Symposium Argentinean Cooperative Group of Haemostasis and Thrombosis. "New Perspectives on Diagnosis
Therapeutic and antithrombotic. "Bs As, 6/8-5-92.

- Scientific Meeting (workshop type.) Argentinean Cooperative Group Haemostasis and Thrombosis.
Topic: Bleeding Time." Bs As, 8-5 - 92.

- II Scientific Meeting 1992. Argentinean Cooperative Group of Haemostasis and Thrombosis.
Topic: "Low Molecular Weight Heparin and antithrombin Therapeutics." Bs As, 06.12.1992.

- III Scientific Meeting 1992. Argentinean Cooperative Group of Haemostasis and Thrombosis.
Theme: "Hepatic and Coagulation." Bs As, 08.14.1992.

- 56 ° Annual Scientific Triduum. Biochemistry Association Argentina. Buenos Aires, 26 to 10/31/1992.

- Symposium Buenos Aires 1992. Latin American Cooperative Group of Haemostasis and Thrombosis.
Theme: "Coronary Angioplasty." Buenos Aires, 1, 12/02/1992.

- II Scientific Meeting 1993. Argentinean Cooperative Group of Haemostasis and Thrombosis.
Topic: Oral anticoagulation: an update. " Bs As, 18.06.1993.

- IIHema Scientific Meeting of the National Academy of Medicine and the Hemophilia Foundation of Argentina. Topic: "Present and future treatment of hemophilia." Bs As, 11.08.1993.

- Buenos Aires 1993 Symposium. CAHT Group. Theme: "heparin. thrombolysis and / or angioplasty in AMI
. " Bs As, 15 and 11/16/1993.

- II CAHT Group Scientific Meeting, jointly with the Stroke Council of the SAC, Bs As, 24.04.1995:
"Coronary artery disease in patients with TIA and stroke: prevalence, implications
prognostic and therapeutic. "
05/22/1995: Risk of stroke in cardiac lesions.
28/11/1995: Thrombophilia family, clinical, diagnostic and therapeutic approach with special
DVT, arterial thrombosis and embolism and ischemic stroke in young people.

- Conference Dr Dahlback (Sweden): Resistance to activated protein C as risk factor for venous thrombosis
. Lab Chromogenics and CAHT group, Bs As, 11.20.1995.

- Joint Scientific Meeting Saetre and Society of Internal Medicine of Buenos Aires
Tribute to the Masters of Hematology. 09/05/1996.

- Italo-Argentine Conference of Hematology, IIHema, National Academy Medicine, 3/4-10-96.
- Ia Scientific Meeting 1997. Argentinean Cooperative Group of Haemostasis and Thrombosis.
Topic: Pathology thrombotic pregnancy. " Buenos Aires, 23/05/1997.

- IIa Scientific Meeting 1997. Argentinean Cooperative Group of Haemostasis and Thrombosis.
Theme: "prothrombotic states." Buenos Aires, 11/07/1997.

- IIIa Argentine Congress of Hemostasis and Thrombosis. CAHT Group, Buenos Aires, 18 to 20/11/1998

- XLIII Annual Meeting of the Sociedad Argentina de Investigación Clínica, Mar del Plata, 26/29/11/98.

- Ibero-American Symposium of Hematology. IIHema Academy Of Medicine, 14/16-4-99

- International Symposium on Hodgkin Lymphoma. Review and Update, Roemmers Foundation,
08/06/1999.

- Ia. CAHT Group Scientific Meeting 2000. Theme: "thrombocytopenia." 05/19/2000.

- Scientific Meeting of the Group IIa CAHT 2000. 06/30/2000.

- XLV Annual Meeting of the Sociedad Argentina de Investigación Clínica, Mar del Plata, 22-25/11/2000.

- British Days of Hematology. Total hours: 13. IIHema, National Academy of Medicine;
April 2001.

- International Symposium on plurimetabolic syndrome; Foundation Roemmers, 04/26/1901.

- International Symposium "Hemolytic Uremic Syndrome," National Academy of Medicine, June 2001.

- International Symposium on Vascular Disease TTP; Roemmers Foundation, 1/10/1919.

- XLVII Annual Meeting of the Sociedad Argentina de Investigación Clínica, Mar del Plata, 22-23/11/2002.

- Symposium on Hemostasis and Thrombosis, CAHT Group, Margulies Foundation, 29/11/1902.

- Attended and presented papers at the XIX Congress and 49th Annual SSC Meeting of the International Society on Thrombosis
and Haemostasis. Birmingham, UK, 12-18 July 2003.

- Symposium Hemostasis and Thrombosis, CAHT Group, Margulies Foundation, 08/08/1903.

- Joint Congress of Biomedical Societies, Mar del Plata, 16-20/11/04.

- Fourth Scientific Meeting CAHT Group, Del Viso, Pilar, 11/26/1904.

- North American Conference of Hematology. IIHema, National Academy of Medicine, 14 and 04/15/1905.

- International Symposium on Hemorrhagic and Thromboembolic Complications in Oncology.
Roemmers Foundation, National Academy of Medicine, 07/01/1905.

- International Symposium on glycoproteins. Tribute to Luis F. Nobel Prize Leloir. National Academy of Medicine and National Academy of Sciences, Physical and Natural Sciences. 09/12/1906.

- Molecular Immunology of Protozoan Infections. HHMI, EMBO, WHO, ANPCyT, CONICET, UNU-
BIOLAC, CABBIO, 19 and 03/20/1907.

- Presentation Dr. Jorge di Paola (University of Iowa) 03/29/1907, Lanari Institute.
Topic: genetic modifiers von Willebrand factor

- Canadian Conference of Hematology. IIHema. National Academy of Medicine, 19 and 20/04/1907.

- XX Congress of the Latin American Group of Haemostasis and Thrombosis (CLAHT) -
Group VIII Argentine Congress of Hemostasis and Thrombosis (CAHT). From 23 to April 26, 2008. Graduate courses


- Course Thrombosis Research Institute Hematologic "Mariano R. Castex", National Academy of Medicine. Buenos Aires. 12/22-05-78.

- Course Haemostasis, Hematological Research Institute 'Mariano R. Castex ", National Academy of Medicine. Buenos Aires. 24/28-5-78.

- Theoretical and Practical Course "Research Methodology and Biostatistics, IIHema, National Academy of Medicine, on days 1, 8, 15, 22 and 29/09/1999.

- Course organized by PE Biosystems of Brazil "DNA Sequencing on the ABI PRISM 310 Genetic Analyzer."
8/12-11-1999
- Theoretical and Practical Course "Introduction to flow cytometry" total hours: 8. IIHema, National Academy of Medicine, 7 and 8 June 2001.

- Basic Biostatistics course of 80 class hours, with a final exam passed. Epidemiologic Research Center, National Academy of Medicine, July 2001.

- Advanced Biostatistics course of 70 class hours, with a final exam passed.
Epidemiologic Research Center, National Academy of Medicine, November 2001.

- Molecular Diagnostics in medicine. Its application to genetic diseases, cancer and infectious
, with a final exam passed. Centre for Research on Porphyrins and Porphyrias
(CIPYP). Department Biological Chemistry. FCEyN, UBA 9/17-12-02.

- Meta-analysis. Epidemiologic Research Center, National Academy of Medicine, the
16 / 3 18 / 5 2004.

- Principles and applications of RNA interference (siRNA), Sociedad Argentina
Research Clinical Genetics Council, 08/31/2005.

- Molecular Diagnostics in medicine. Its application to genetic diseases, cancer and infectious 2005 with approved final assessment (90 hours duration). Centre for Research on Porphyrins and Porphyrias (CIPYP). Department of Biological Chemistry. FCEyN, UBA. 8/25-11-05.

- Minicourse: Biosynthesis Combinatorics: New Technology for Generation of Therapeutic Agents. Carried out during the 50th Annual Meeting of the Sociedad Argentina de Investigación Clínica, Mar del Plata, 29 to December 2, 2005.

- Mini-Course: Analysis and Interpretation of Microarray Data. GE Healthcare Bio-Sciences. Molecular Classification of Prostate Tumors Using Intronic Arrays. Carried out during the 50th Annual Meeting of the Sociedad Argentina de Investigación Clínica, Mar del Plata, 29 to December 2, 2005.

- Minicourse: Mutagenesis Techniques Applied to the Study of Protein Structure and Function. Carried out during the 50th Annual Meeting Sociedad Argentina de Investigación Clínica, Mar del Plata, 29 to December 2, 2005.



PUBLICATIONS in refereed journals

1 - Meschengieser S, Woods AI, Schattner M, Lazzari MA: Association of hemorrhagic and thrombotic phenomena in myeloproliferative syndromes. Medicina (Buenos Aires) 41:267-273, 1981.

2 - Woods AI, Sutton NM, Kempf A, Casillas G, Lazzari MA: Use of plasma ultrasonicated as diluent in the art metering ristocetin cofactor. Blood 30:999-1006, 1981.

3 - Woods AI, Vargas J, Berri G, Kreutzer G, Meschengieser S, Lazzari MA: Antithrombotic therapy in Children and adolescent. Thromb. Res. 42:289-301, 1986.

4- Woods AI and Lazzari MA: Aspirin effect on platelet antiplasmins release. Thromb Res. 47:269-277, 1987.

5- Meschengieser S, Blanco A, Woods AI, Maugeri N, Fernández J, Dupont J, Lazzari MA: Intraplatelet levels of FvW:Ag and fibrinogen in myeloproliferative disorders. Thromb. Res. 48:311-320, 1987.

6- Woods AI. and Lazzari MA: Aspirin effect on the release of plasminogen activators inhibitors by human platelets. Thromb. Res. 52:119-125, 1988.

7- Farías C, Kempfer A, Blanco A, Woods AI, Lazzari MA: Visualization of the multimeric structure of von Willebrand Factor by immunoenzymatic stain using Avidin-Peroxidase Complex instead of Avidin-Biotin-Peroxidase Complex. Thromb. Res. 53:513-518, 1989.

8- Woods AI, Frontroth JP, Lazzari MA: Effect of protease inhibitors on the ristocetin cofactor activity. Rev. Iberoamer. Tromb. Hemostasia. 2:47-48, 1989.

9- Woods AI, Nadra C, Lazzari MA: The effect of venous occlusion on the PAI and anitplasmins release from platelets. Thromb. Res. 56:491-495, 1989.

10- Grand B, Blanco A, Riveros D, Ventura A, Maugeri N, Woods A, Lazzari MA: Congenital Factor XIII deficiency associated with von Willebrand's disease. Am. J. Hematol. 35:208-209, 1990.

11- The Ridogrel Versus Aspirin Patency Trial (RAPT). Randomized Trial of Ridogrel, a combined TXA2 Synthase Inhibitor and TXA2/ prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. Circulation 89:588-595, 1994.

12- Woods AI, Santarelli M, Lazzari MA: The inhibitory effect of platelets on fibrinolysis in diabetic patients. Thrombosis Research 76:391-396,1994.

13- Farias CE, Gimenez JC, Kempfer AC, Singer E, Woods AI, Santarelli MT, Lazzari MA. Ionizing radiation increases concentration of plasma von willebrand factor in cebus apella paraguayanus monkeys. Thrombosis Research 88,81-87,1997.

14- Kempfer AC, Silaf MR, Farias CE, Carballo GA, Woods AI, Lazzari MA. Binding of von Willebrand factor to collagen by flow cytometry. Am. J. Clin Pathol. 111,418-423,1999.

15- Woods AI, Meschengieser SS, Blanco AN, Salviú MJ, Farias CE, Kempfer AC, Lazzari MA. Clinical features and laboratory patterns in a cohort of consecutive Argentinian patients with von Willebrand`s disease. Haematologica 86,420-427;2001.

16- Sánchez-Luceros A, Meschengieser SS, Woods AI, Blanco AN, Kempfer AC, Casais P, Salviú MJ,
Lazzari MA. Acquired von Willebrand factor abnormalities in myeloproliferative disorders and other
hematologic diseases: a retrospective analysis by a single institution. Haematologica 87:264-70; 2002.

17- Sanchez-Luceros A, Meschengieser SS, Votta R, Casais P, Woods AI, Nadal MV, Salviú MJ, Lazzari MA. Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium. Blood Coagulation and Fibrinolysis 14:647-651; 2003.

18- Kempfer AC, Farias CE, Amaral MM, Silaf MR, Woods AI, Carballo GA, Lazzari MA. Control of von Willebrand factor multimer size by a fibronectin related substance. Blood Coagulation and Fibrinolysis 14:441-8; 2003.
19- Sanchez-Luceros A, Farías CE, Amaral MM, Kempfer AC, Votta R, Marchese C, Salviú MJ, Woods AI, Meschengieser SS, Lazzari MA. Von Willebrand factor-cleaving protease (ADAMTS 13) activity in normal non-pregnant women, pregnant and delivery women. Throm Haemost 2004;92:1320-6.

20- Favaloro EJ, Lilicrap D, Lazzari MA, Cattaneo M, Mazurier C, Woods A, Meschengieser S, White A, Kempf AC, Hubbard A, Chang A. von Willebrand Disease: Laboratory aspect of diagnosis and Treatment. Haemophilia 2004; 10: (suppl.4), 164-168.

21 - Casais P, Carvalho GA, Woods AI, Kempf AC, Farias CE Grosso SH, Lazzari MA. Within sustitution encoded R924Q Exon 21 of the von Willebrand factor gene related to wild Bleeding phenotype. Thromb Haemost 2006; 96:228-30.

22 - Sánchez-Luceros A; Meschengieser SS; turds K, Ariza A, Woods AI, couples P, White NA, AC Kempf, Maria A Lazzari. Clinical Evaluation of the safety of desmopressin in women During Pregnancy With A low plasma von Willebrand factor level and Bleeding history. Thromb Res 2007; 120.387-90.

PUBLICATIONS Refereed Journal without

1 - Woods AI, Meschengieser S, Lazzari MA: Platelet function in diabetic patients. Bulletin of the National Academy of Medicine. 59:297-302, 1981.

2 - Meschengieser S, Woods AI, Lazzari MA: Oral anticoagulation in pregnant patients with mechanical valve prostheses. Bulletin of the National Academy of Medicine. 65:359-363, 1987.

3 - Meschengieser S, Bermejo E, Maugeri N, Woods AI, Blanco A, Pieroni G, Lazzari MA: Use of DDAVP in patients with von Willebrand disease and thrombocytopathies. Bulletin of the National Academy of Medicine. 67:135-145, 1989.

4 - Bermejo E, Meschengieser S, Woods A, Peñalba L, Pieroni G, Lazzari MA: DDAVP: Changes of hemostasis caused by its use. Prensa Médica Argentina 79:376-380,1992.

5 - Farias CE, Kempf AC, Woods A, Lazzari MA. Multimeric population analysis of platelet von Willebrand factor after DDAVP administration. Bulletin of the National Academy of Medicine 71:509-515, 1993.

6 - Peñalva L, Dib Ashub M, Blanco A, Woods AI, Lazzari MA. Fibrinolytic response to 1 - deamino-d-arginine vasopressin (DDAVP) in patients with impaired hemostasis. Bulletin of the National Academy of Medicine 71:81-84, 1993.

7 - Woods A, Meschengieser S, White, AN, Salviú MJ, Farias CE, Kempf BC Lazzari MA. Von Willebrand disease, the most common bleeding disorder. Bulletin of the National Academy of Medicine 79:275-290, 2001.
ABSTRACTS PUBLISHED IN JOURNALS OF CONFERENCE NATIONAL PERIODICAL

1 - Lazzari MA, Schattner M, Woods AI, Arce R: Controls of antithrombotic therapy. Medicina (Buenos Aires) 39 (6): 715, 1979 (to 15).

2 - Meschengieser SS, Woods AI, Lazzari MA: Platelet function in diabetic patients. Medicina (Buenos Aires) 41 (6): 692, 1981 (to 88).

3 - Woods AI, Lazzari MA: fibrinolytic activity in diabetic patients. Medicina (BsAs) 41 (6): 693, 1981 (to 89).

4 - Woods AI, Sutton N, Lazzari MA: Use of plasma ultrasonicated in assessing the ristocetin cofactor. Medicine (Buenos Aires) 43 (6 / 2): 828, 1983 (to 205).

5 - White A, Meschengieser SS, Woods AI, Farias C, Maugeri N, Bermejo E, Pieroni G, Ventura A, Lazzari MA: myeloproliferative syndromes (SMP) and acquired von Willebrand (vWA). Medicine (Bs.As) 48 (6): 624, 1988 (a.192)

6 - Kampfer A, Frontroth J, Farias C, Bermejo E, Woods AI, Lazzari MA: Involvement of serum components in the adhesion of von Willebrand factor (vWF) to the subendothelium in perfusion chamber. Medicina (Buenos Aires) 49 (6): 438, 1989 (a.109)

7 - White A, Grand B, Pieroni G, Peña L, Voto L, Ventura A, Woods A, Lazzari MA: Complex factor VIII / von Willebrand factor (VIII / vW) in pregnancy-induced hypertension. Medicine 52 (sup II): 391, 1992.

8 - Kampfer A, Farias C, Woods A, Frontroth JP, Bermejo E, Lazzari MA: multimeric structure of von Willebrand factor (vWF), platelet after administration of DDAVP. Medicine 52 (suppl II): 392, 1992.

9 - Kampfer A, Farias C, Woods A, Frontroth JP, Bermejo E, Lazzari MA: multimeric structure of von Willebrand factor (vWF) under high shear rate. Medicine 52 (suppl II): 391.1992.

10 - Woods AI, Kampfer AC, Effect of collagen and aspirin on the release of PAI-1 and intraplatelet t-PA. Medicine 53 (suppl II), 43.1993 (a 95).

11 - Bermejo E, Woods AI, Meschengieser S, Lazzari MA. Prolongation of bleeding time and platelet function abnormalities in patients with von Willebrand disease. Medicine 53 (suppl II); 74, 1993 (to 155).

12 - Szwarcer E, Giuliani AR, White A, Palumbo G, Bartomioli M, Orlando S, Woods A, Aguero G, Baitch L, Villafañe S, Lanari E, Amaya ED, Diaz R, ECLA Study Group 2, Bs As Argentina. Relationship between parameters of haemostasis, coronary patency and bleeding in the 2-RAPT ECLA study. 1 Argentine Congress Hemostasis and Thrombosis, group CAHT, Mar del Plata, 7 to 10/09/1994.

13 - Farias CE, Woods AI, Bermejo E, Meschengieser S, Kampfer AC, Lazzari MA. Patients with von Willebrand disease type 1. Expression of different subtypes according to the intraplatelet von Willebrand factor. Medicine 54, 494, 1994 (to 31).

14 - Farias CE, Kempf AC, Woods AI, Bermejo E, Lazzari MA. Comparisons of the Platelet fibronectin in patients with von Willebrand disease type 1. normal platelet and platelet discordant, before and after infusion of desmopressin. Medicine 54, 494, 1994 (to 32).

15 - Farias CE, Kempf AC, Woods AI, Lazzari MA. Effect of blood group and sex in the content of von Willebrand factor (vWF) intraplatelet. Medicine 55, 83, 1995.

16 - Farias CE, AC Kampfer, Meschengieser S, Woods AI, Blanco A, Lazzari MA. Monitoring the response to desmopressin (DDAVP) in patients with von Willebrand (vW) using the collagen binding assay. Medicine 56, 621.1996 (A261)

17 - Kampfer AC, Farias CE, MR Silaf, Carballo GA, Woods AI, Lazzari MA. Detection of the binding of von Willebrand Factor (vWF) to collagen and vWf: Ag by flow cytometry. Medicine 57 (suppl 4): 2.1997 (8).

18 - Farias CE, AC Kampfer, Meschengieser S, Carballo GA, Silaf MR, Blanco A, Woods AI, Lazzari MA. Usefulness of a functional assay based on the binding of von Willebrand factor (vWf) to FVIII to classify patients with von Willebrand disease. Medicine 57 (suppl 4): 4.1997 (at 14).

19 - Woods AI, Maugeri N, Kampfer AC, Lazzari MA. Effect of low shear rate on the release of PAI-1 Platelet; their inhibition with aspirin. Medicine 57 (suppl 4): 5.1997 (at 17).

20 - Woods AI, Blanco, AC Kampfer, Meschengieser SS, Lazzari MA. Our experience in the diagnosis of von Willebrand disease. Medicine 58 (5 / 2), 668.1998 (a 460)

21 - Woods AI, Blanco, AC Kampfer, Meschengieser SS, Lazzari MA.Penetrancia the phenotype of the disease von Willebrand type 1 and 2A. Medicine 58 (5 / 2): 668, 1998 (to 461)

22 - Farias CE, Kempf AC, Carballo GA, Silaf MR, Casais P, Woods A, Grosso S, Lazzari MA. Frequency of the Arg 91 Gln mutation in von Willebrand disease type 2N. Medicine 58 (5 / 2): 668, 1998 (to 462)

23 - Sanchez Luceros A, Ariza A, Casais P, Woods AI, Meschengieser SS, Lazzari MA. Use of desmopressin in pregnant women with von Willebrand disease. Medicine 59 (5 / 2): 560, 1999 (to 9).

24 - Woods AI, Kempf A, Silaf M, Farias C, Grosso S, Carballo G, Lazzari M. Inhibition of ristocetin cofactor activity by the presence of EDTA. Medicine 60 (5 / 2): 790; 2000 (241).

25 - Farias C, Kempf A, Sanchez Luceros A Silaf M, Woods A, Carvalho G, Lazzari M. Extra-large multimers of von Willebrand factor in normal pregnant women in the third quarter. Medicine, 60 (5 / 2): 790, 2000 (242).

26 - Kempf AC, Carvalho GA, Farias C, Silaf MR, Amaral MM, Woods AI, Lazzari MA. Relationship between fragments of fibronectin (Fn) high affinity for heparin and the protease that the Clive
von Willebrand factor (VWFCP). Medicine 61 (5 / 2): 770, 2001 (the 393).

27 - Kempf AC Farias C, Silaf MR, Carvalho GA, Amaral MM, Woods AI, Lazzari MA. Differentiation between the protease related to fibronectin (PRFN) described other proteases that cleave the von Willebrand factor (VWF) and matrix metalloproteinases (MMP). Medicine 62 (5): 409, 2002 (to 65).

28 - Farias C, Kempf A, Amaral MM, Woods AI, Nadal V, Carballo G, Meschengieser S, Lazzari MA. Virtual decrease of protease cleaving von Willebrand factor (VWFCP) after administration of desmopressin (DDAVP). Medicine 62 (5): 442, 2002 (to 212).

29 - Carballo GA, Woods AI, Farias C, Kampfer AC, Lazzari MA. Von Willebrand disease type 2N. Molecular biology. Medicine 62 (5): 442, 2002 (to 213).

30 - Woods AI, Meschengieser SS, White A, Lazzari MA. Risk of major bleeding in patients with von Willebrand disease type 1. Medicine 62 (5): 444, 2002 (to 221).

31 - Woods AI, Nadal MV, Meschengieser SS, Blanco AN, Lazzari MA. Influence of intra-platelet VWF in the presence of major bleeding in surgery. Medicine 63: 654, 2003 (to 526).

32 - Kampfer AC, Farias C, Sanchez-LUCERO A, Amaral MM, Grosso S, Carballo G, Woods A, Lazzari MA. Discordance between levels of von Willebrand factor (VWF) and factor VIII (FVIII) hemophilia or not related to the variant 2 N von Willebrand disease. Medicine 63:654, 2003 (to 528).

33 - Nadal MV, Blanco AN, Woods AI, Meschengieser SS, Grosso SH, Salviú MJ, Lazzari MA. Von antigen Platelet Willebrand (VWF: Ag-i) in patients with mucocutaneous bleeding and normal levels of plasma von Willebrand factor (VWF: Ag). Medicine 63: 654, 2003 (to 529).

34 - Carballo GA, Woods AI, Kampfer AC, Farías CE, Amaral MM, Lazzari MA. R924Q substitution in a family with a slight decrease of FVIII binding to VWF. Medicine 63:656, 2003 (to 534).

35 - Carballo GA, Woods AI, Vera E, Casais P, Aletti G, Farías CE, Kempf AC, Lazzari MA. Genetic alterations of von Willebrand factor in 22 family members in Argentina. Medicine 64: (suppl II), 2004 (to 400).

36 - Woods AI, Blanco AN, Nadal MV, Meschengieser SS, Grosso SH, Lazzari MA. Fibrinolytic response to DDAVP in patients with type 1 VWD likely without major bleeding in surgery. Medicine 64: (suppl II), 2004 (to 678).

37 - Keller L, Woods AI, Kampfer AC, Farías CE, Grosso N, Lazzari MA. Validation of the Conformation Sensitive Gel Electrophoresis (CSGE) as a method of screening of exon 22 of von Willebrand factor in the diagnosis of von Willebrand disease (VW) 2N. Medicine 65: (suppl II), 2005 (to 65).

38 - Marti A, Casais P, Kampfer AC, Woods A, White A, Meschengieser S, Lazzari MA. Von Willebrand disease subtype 2B and management of labor. XVII Argentine Congress of Hematology. 60 th Anniversary of the Society Argentina Hematology. Córdoba. 2-5.11.2005.

39 - Keller L, Woods AI, Farías CE, Sanchez-LUCERO A, Grosso N, Kampfer AC, Powazniak YP, Calderazzo JC, Lazzari MA. Association of von Willebrand type 2N and type 2M Vicenza. Medicine 66: (supl.II), 2006 (to 162).

40 - Carrivale M, Kampfer AC, Woods AI, Vizcaychipi K, Astudillo CG, Sanchez Luceros A, Lazzari MA. Identification of patients with shortened survival of von Willebrand factor. Medicine 67 (suppl III), 2007 (to 14).

41 - Woods AI, Blanco AN, Grosso SH, JC Calderazzo, Meschengieser SS, Lazzari MA. Differential diagnosis between type 3 VWD and severe Type 1 by the response to DDAVP ELT time. Medicine 67 (suppl III), 2007 (to 9).

42 - Keller L, Kampfer AC, Woods AI, Sanchez Luceros A, Powazniak And Carrivale M, Lazzari MA. New polymorphisms in the ADAMTS gene intron 13. Medicine 67 (suppl III), 2007 (to 23).




ABSTRACTS PUBLISHED IN JOURNALS OF INTERNATIONAL CONFERENCE PERIODICAL

1 - Meschengieser S, Woods AI, Lazzari MA: Association of hemorrhagic and thrombotic phenomena in myeloproliferative syndromes. VI Congress of Hemostasis and Thrombosis Latinomaricano. Bs.As, October 1980. Abstract book p.13.

2 - Woods AI, Meschengieser S, Sutton M, Lazzari MA: Correlation between ristocetin cofactor levels and various parameters of platelet aggregation in diabetic patients. VI Latin American Congress of Hemostasis and Thrombosis. Buenos Aires, October 1980. Abstract book p.12.

3 - VIII International Congress of Haematology. Montreal, Canada, October 1980. Abstract Book p. 145.

4 - Woods AI, Lazzari MA: Platelets and fibrinolysis. VII Latin American Meeting of Haemostasis and Thrombosis. San José, Costa Rica, July 1981. Book of Abstracts.

5 - Woods AI, Meschengieser S, Sutton M, Lazzari MA. Platelet function parameters in diabetic Patients. Thromb Haemost 1981, 46 (1). (To 1413).

6 - Meschengieser S, Woods AI, Schattner M, Lazzari MA: Antiplatelet action of ticlopidine on thrombotic Normal Subjects and Patient. VII International Congress on Thrombosis. Haemostasis 1982, 12:159.

7 - Lazzari MA, Woods AI, Sutton N: Use of ultrasonicated for the dosage of plasma ristocetin cofactor. IX International Congress on Thrombosis and Haemostasis. Stockholm, Sweden. 3 / 8 Julio 1983. Thromb. Haemost 1983; 50 (1): 224 (the 764).

8 - Woods AI, Vargas J, Berri G, Kreutzer G, Meschengieser S, Lazzari MA: Our experience in the management of Anticoagulation in children and Adolescent. XX Congress of International Society of Hematology. Bs.As., September 1984. Abstracts Book.

9 - Woods AI, Lazzari MA: Action of aspirin on platelet antiplasmin release. XI Congress of the Association of Pharmacology and II Latinomamericana Congress of the American Society for Clinical Pharmacology and Therapeutics. Buenos Aires, 24/29 November 1986. Book of Abstracts (a.227).

10 - Meschengieser S, Woods AI, Lazzari MA: Anticoagulation in pregnancy in Patients with cardiac valve prosthesis. Thromb. Haemost. 1987, 58 (1): 130 (to 467).

11 - Woods AI, Lazzari MA: Aspirin effect on platelet antiplasmins release. Thromb. Haemostas.1987, 58 (1): 189 (at 698).

12 - Woods AI, Lazzari MA: Aspirin failure to Inhibit the release of plasminogen Activator inhibitors by human Platelets. Thromb. Haemost. 1987, 58 (1): 94 (at 327).

13 - Lazzari MA, Woods AI: Platelets and fibrinolysis. Conference. X Congress of Hemostasis and Thrombosis. Latin American Cooperative Group of Haemostasis and Thrombosis. Venezuela, in September 1987.

14 - Grand B, Riveros D, Blanco A, Maugeri N, Ventura A, Woods AI, Lazzari MA: Congenital factor XIII deficiency associated with von Willebrand disease. XVIII International Congress of the World Federation of Hemophilia. Madrid, Spain. 31/05/1988. Abstracts Book (50).

15 - Woods AI, Lazzari MA: Platelet antiplasmins release and calcium blockers. X International Congress on Thrombosis. Athens, Greece. 22/27-05-88. Abstract Book (200).

16- XI Congreso Latinoamericano de Hemostasia y Trombosis 1988. Grupo Cooperativo Latinoamericano de Hemostasia y Trombosis. La Habana, Cuba, 16/19-05-88. Libro de Resúmenes.

17- Woods AI, Nadra C, Lazzari MA: Platelet PAI-1 in venous stasis. VI Meeting of the Danubian League against Thrombosis and Haemorrhagic disorders. Viena, Austria, 31-05/03-06-89. Abstract Book.

18- Woods AI, Nadra C, Lazzari MA: Platelet antiplasmins in venous occlusion. VI Meeting of the Danubian League against Thrombosis and Haemorrhagic disorders. Viena, Austria, 31-5/3-6-89. Abstract Book.

19- Woods AI. Lazzari MA: Platelet PAI-1 released calcium blockers. Thromb. Haemostas. 1989; 62 (1):402 (a 596 1279).

20 - White A, Meschengieser S, Woods A, Farias C, Maugeri N, Bermejo E, Pieroni G, Ventura A, Lazzari MA: von Willebrand abnormalitites in myeloproliferative syndromes. Thromb. Haemost. 1989, 62 (1): 223 (at 690).

21 - Fondevila C, Meschengieser S, Bermejo E, Woods AI, Pieroni G, Lazzari MA. Hemostatic complications during childbirth in patients with von Willebrand disease. XII International Congress of Hemostasis and Thrombosis, Buenos Aires, November 1991. Book of Abstracts. (To 112).

22 - Fondevila C, Meschengieser S, Bermejo E, Woods AI, Pieroni G, Lazzari MA. Platelet adhesiveness in von Willebrand disease during pregnancy. XII International Congress Hemostasis and Thrombosis, Buenos Aires, November 1991, Book of Abstracts. (To 111).

23 - Woods AI, Lazzari MA antifibrinolytic platelet activity in diabetic patients. XII International Congress of Hemostasis and Thrombosis. Buenos Aires, November 1991. Book of Abstracts (to 155).

24 - Szwarcer E, Giuliani AR, White A, Palumbo G, Bartomioli M, Orlando S, Woods A, Aguero G, Baitch L, Villafañe S, Lanari E, Amaya ED, Diaz R, ECLA 2, Study Group: Relationship of Hemostasis Parameters to coronary patency and bleeding in 2 RAPT ECLA Trial XVth Congress of the European Society of Cardiology, Nice, France, August 29-September 2, 1993.

25 - Woods AI, Kampfer AC, Lazzari MA. Effect of collagen and aspirin on the intraplatelet PAI-1 and t-PA release. XXV Congress of the I.S.H. Cancun, Mexico. Abril 17/22-1994 (a 604).

26- Meschengieser S, Farias CE, Woods AI, Bermejo E, Kempfer AC, Lazzari MA. Intraplatelet von Willebrand factor and response to DDAVP. XXV Congress of the I.S.H. Cancun, Mexico abril 17/22-1994 (a 568).

27- Meschengieser S, Woods AI, Bermejo E, Lazzari MA. Different patterns in the response to intravenous DDAVP. XXV Congress of the I.S.H. Cancun, Mexico. abril17/22-1994 (a 566).

28- Woods AI, Schattner M, Lazzari MA. PAI-1 and antifibrinolytic activity released by platelets treated with cationized human IgGs. Thromb. Haemostas. 1995; 73 (6). (a 419).

29- Farias C, Meschengieser S, Woods AI, Bermejo E, Funes S, Kempfer AC, and Lazzari MA. Relationship between intraplatelet von Willebrand factor and response to DDAVP. XV Congress of the ISTH. Jerusalem, Israel, junio 11-16, Thromb. Haemostas. 1995; 73 (6). (a 1002).

30- Kempfer AC, Farias CE, Woods AI, Cardoso MA, Lazzari MA. The effect of high shear rat and a plasma fractyion on von Willebrand factor multimers size. Thromb. Haemostas. 1995; 73 (6). (a 1013).

31- Woods AI, Maugeri N, Kempfer AC, Lazzari MA. Effect on the low shear rate on the release of intraplatelet PAI-1. Its inhibition with aspirin. Thromb. Haemostas. 1997; 77 (suppl). (a PS-469)

32- Farias CE, Kempfer AC, Carballo GA, Blanco A, Woods AI, Meschengieser S, Lazzari MA. Laboratory monitoring of Desmopressin (DDAVP) using collagen binding assay (CBA). Thrombo. Haemostas. 1997, 77 (suppl) (a PS-2846).

33 - Farias CE., Kempfer AC., Carballo GA., Silaf MR., Salviu J., Woods AI., Meschengieser S., Lazzari MA. Caracterización parcial type 2N en la enfermedad de von Willebrand using fenotípicas y Técnicas genotípicas. Symposium Internacional. grupo CLAHT, Rio de Janeiro, Brasil, 16 y 07/17/1998.

34 - AC Kempfer., Silaf MR., Farias CE., Carballo GA., Woods AI., Lazzari MA. Binding of von Willebrand factor to collagen by flow citometry. Citometry Suppl. 9, 133, 1998 (in CT79).

35- Woods AI, Meschengieser S, Blanco A, Kempfer C, Santarelli MT, Lazzari MA. Our experience in the diagnosis of von Willebrand disease. XVII Congress of the International Society on Thrombosis and Haemostasis. Washington, 14-21/8/1999. Thromb Haemost (Suppl):132, 1999 (a 408).

36- Woods AI, Meschengieser S, Blanco A, Kempfer A, Lazzari MA. Prevalence of phenotype of von Willebrand disease type 1 and 2A. XVII Congress of the International Society on Thrombosis and Haemostasis. Washington, 14-21/8/1999. Thromb Haemost (Suppl):132, 1999 (a 409)

37- Woods AI, Kempfer CA, Silaf MR, Farias CE, Grosso S, Lazzari MA. EDTA-dependent low ristocetin cofactor activity. Thromb Haemost. 2001.

38 - Farías C., Kempf A., Sánchez Luceros A., Silaf M., Woods AI, Carbone G., Lazzari MA. Ultra large (UL) von Willebrand Factor multimers in Normal Pregnant Women at the third trimester. Thromb Haemost 2001 (to 785)

39 - Woods AI, Meschengieser SS, Blanco AN, Lazzari MA. Platelet VWF as a marker predictive of major bleeding in surgery. XVIII International Congress of Hemostasis and Thrombosis CLAHT Group, May 18-21th 2003, Rio de Janeiro, Brazil. (30).

40 - Grosso S, White A, Casais P, Nadal MV, Woods A, Lazzari MA. Deficiency of factor VII (FVII): frequency, clinical features and association with abnormal von Willebrand factor-VIII. XVIII Congress Internacional de Hemostasis y Trombosis Grupo CLAHT, mayo 18-21de 2003, Rio de Janeiro, Brasil. Revista Brasileira de Hematologia e hemoterapia: Vol 25 (supl1), abs. 035, pag. 33; mayo 2003.

41- Woods AI, Meschengieser SS, Blanco AN, Lazzari MA. Incidence of major haemorrhages related to surgery in type 1 von Willebrand's disease. J Thromb Haemost, 2003 (a 1682).

42- Carballo GA, Kempfer AC, Woods AI, Farias CE, Lazzari MA. Comparative study of conformation sensitive gel electrophoresis and DNA sequencing for polymorphisms and mutation detection in von Willebrand disease type 2N. J Thromb Haemost, 2003 (a 1681).

43- Farias C, Kempfer AC, Amaral MM, Woods AI, Nadal MV, Carballo GA, Meschengieser SS, Lazzari MA. Virtual decrease of von Willebrand Factor-cleaving protease (ADAMTS 13) after infusion of desmopressin (DDAVP). J Thromb Haemost, 2003 (a 1675).

44- Carballo GA, Woods AI, Vera E, Casais P, Aletti G, Farías C, Kempfer AC, Lazzari M A. Genetic Study Of von Willebrand Factor In Twenty-two Members Of An Argentinian Family. J Thromb Haemost, 2005 (a 863).

45- Woods AI; Blanco AN; Nadal MV; Meschengieser SS; Grosso SH; Lazzari MA. Evaluation of Fibrinolytic Activity and major hemorrhages in Probable Type 1 von Willebrand Disease. J Thromb Haemost, 2005 (a 263).

46- Woods AI, Keller L, Kempfer AC, Farias CR, Casais P, Lazzari MA. CSGE to scan the exon 22 of von Willebrand factor gene for diagnosising von Willebrand disease 2N. Pathophysiol Haemost Thromb 35 (1-2), Proceedings and Abstracts from the 19th International Congress on Thrombosis. Tel Aviv, Israel, May 2006.

47- Casais P, Meschengieser S, Kempfer C, Woods A, Sanchel Luceros A, Lazzari MA. Pregnancy of type 2B vWD. World Federation of Haemophilia Congress 2006. Vancouver, Canada. 30 PO 906.

48- Woods AI, Sanchez-Luceros A, Blanco AN, Grosso SH, Kempfer AC, Lazzari MA. Is there any correlation between fibrinolytic activity and bleeding score in type 1 and possible type 1 von Willebrand disease?. J Thromb Haemost 2007; vol 5, Suppl 2. (P- W 178).

49- Kempfer AC, Farias C, Powazniak Y, Woods AI, Calderazzo J, Keller L, Lazzari MA. VWF-cleaving serine proteases isolation different from ADAMTS 13. J Thromb Haemost 2007; vol 5, Suppl 2. (P- M 298).

50- Keller L, Woods AI, Kempfer AC, Farías CE, Sanchez-Luceros A, Grosso SH, Lazzari MA.
An association of Vicenza and Normandy variants von Willebrand disease (VWD). J Thromb Haemost 2007; vol 5, Suppl 2. (P- W 161).

51- Kempfer AC, Keller L, Farias C, Woods AI, Sanchez-Luceros A, Powazniak Y, Carrivale M, Lazzari MA. abstract N° 1321 - Three new polymorphisms located in the intron 2 of the ADAMTS 13 gene. J Thromb Haemost 2007; vol 5, Suppl 2 (P- M 297).

52- Sanchez-Luceros A, Meschengieser SS, Turdó K, Woods AI, Kampfer AC, Blanco AN, Lazzari MA. Clinical and biological response to desmopressin in Children with von Willebrand disease. J Thromb Haemost 2007, vol 5, Suppl 2. (P-S 248).

53 - Woods AI, Blanco AN, Grosso SH, JC Calderazzo, Meschengieser SS, Lazzari MA. Differential diagnosis between type 3 VWD and severe Type 1 by the time response to DDAVP ELT. XX Congress CLAHT Group, Eighth Congress of CAHT Group (P-135).

54 - Carrivale M, Kampfer AC, Woods AI, Vizcaychipi K, Astudillo OG, Sánchez Luceros A, Lazzari MA. Identification of patients with shortened survival of von Willebrand factor (VWF). XX Congress CLAHT Group, Eighth Congress of CAHT Group (P- 116).

55 - Gross S, Bastos L, Ingratti M, Vizcaychipi K, Woods AI, Meschengieser SS, Blanco AN, Lazzari MA. VWD and lupus anticoagulant: FBI dilution curves in the evaluation of response to DDAVP. XX Congress CLAHT Group, Eighth Congress of CAHT Group (P-084). TEACHING




- Refresher Course conducted by the National Institute of Cardiology. Buenos Aires, October 1980.
Subject: Participation of platelets in the clotting mechanism. Platelet coagulant activity.

- parallel course to the VI Congress of Hemostasis and Thrombosis. Latin American Cooperative Group of Haemostasis and Thrombosis. Buenos Aires, October 1980.
Subject: Participation of platelets in the clotting mechanism. Platelet coagulant activity.

- Refresher Course for Cardiologists, conducted by the Cardiology Division, Hospital Durand. Buenos Aires, April 1981.
Subject: Laboratory controls during treatment with oral anticoagulants.

- Haemostasis and Thrombosis course for graduates, conducted by the Association Argentina Biochemistry. Buenos Aires, October 1981.
Topics: platelet ultrastructure. Participation of platelets in the clotting mechanism. Platelet coagulant activity.

- Haemostasis and Thrombosis Course. ESSEX laboratories. Buenos Aires, October 1981.
Topic: platelet ultrastructure. Participation of platelets in the clotting mechanism.

- Haemostasis and Thrombosis course, parallel to the V Argentine Congress of Biochemistry, Biochemistry Association by Argentina. Buenos Aires, 01/06-11-81.
Topic: platelet ultrastructure. Participation of platelets in the clotting mechanism. Platelet coagulant activity.

- Course of Hematology and Hemostasis of graduate students, conducted by the Acute Hospital Interzonal "Dr. Gregorio Alfaro." Biochemical College of the Province of Buenos Aires, 08/19/1985.
Topic: thromboelastography.

- Refresher Course and systematization Hematological Pathology, conducted by the Society of Hematology Argentina, Buenos Aires 06/30/1986.
Topic: Testing for the study of platelet function, bleeding time, platelet adhesiveness in vitro, ristocetin cofactor, circulating platelet microaggregates, degranulation studies: labeling with mepacrine.

- Refresher Course conducted by the Department of Haemostasis and Thrombosis. Institute of Hematologic Research "Mariano R. Castex", National Academy of Medicine.
Subject: Participation of platelets in the clotting mechanism. Platelet coagulant activity. Platelet Factor 3, Platelet Factor 4 and ß-Thromboglobulin: biochemistry and clinical interest. Detection of circulating platelet microaggregates: determination and clinical application. Laboratory control of oral anticoagulant treatment. Ristocetin Cofactor: determination and clinical usefulness. Von Willebrand disease: classification. Platelet specific proteins. From 1979 to 1993.

- Refresher Course conducted by the Department of Haemostasis and Thrombosis. Institute of Hematologic Research "Mariano R. Castex", National Academy of Medicine. Module 1: "von Willebrand Disease." From 1994 to present.
Topic: ristocetin cofactor in plasma and platelets: identification and clinical utility.

- IIHema Joint Meeting of the National Academy of Medicine and the Association Argentina Hemotherapy and Immunohematology. Practical Module "Flow Cytometry." Bs As, 11.27.1998.
Topic: Determination of ristocetin cofactor in plasma, platelets, and cryoprecipitate.

- Haemostasis Module Career Specialist Clinical Biochemistry, Haematology area, Faculty of Pharmacy and Biochemistry, UBA, 06/08/2000.
Topic: Ristocetin Cofactor of: determining biochemical and clinical implications "

- Professional Development Course 2000. "Coagulation and Platelets: technical aspects." Argentina Technicians Association Clinical Laboratory. 14/7/2000.
Topic: Determination of ristocetin cofactor in plasma, platelets and cryoprecipitate: determination and clinical usefulness.

- Theoretical and Practical Course of Hemostasis and Thrombosis by the Department of Haemostasis and Thrombosis, 2002. Institute of Hematologic Research "Mariano R. Castex", National Academy of Medicine. Module: Methodology applied to the study of thrombotic risk markers.
Topic: Determination of ristocetin cofactor in plasma, platelets and cryoprecipitate: determination and clinical usefulness.

- theoretical and practical course "Update in Hemostasis and Thrombosis" by the Department of Haemostasis and Thrombosis, 2003. Institute of Hematologic Research "Mariano R. Castex", National Academy of Medicine.
Topic: Ristocetin cofactor activity: aggregation with ristocetin.
ristocetin cofactor activity in cryoprecipitate and concentrates of FVIII / VWF.

- theoretical and practical course "Update in Hemostasis and Thrombosis" by the Department of Hemostasis and Thrombosis, 16-23-5-2005. Module 1: Alterations in coagulation, with a total of 1:30 pm Chair. Institute of Hematologic Research "Mariano R. Castex", National Academy of Medicine.
Topic: von Willebrand Factor. Von Willebrand disease and its variants.
ristocetin cofactor activity in plasma and platelets. Aggregation with ristocetin.
ristocetin cofactor activity in cryoprecipitate and concentrates of FVIII / VWF.
search techniques for mutation screening for VWD 2 N.

- theoretical and practical course organized by the Career Specialist in Clinical Biochemistry, Haematology area, 05.31.2006, Haemostasis Module "von Willebrand disease, diagnosis and classification."

- Speaker at the Second Scientific Meeting of the Argentina Society of Hematology on "Importance Molecular diagnosis of mutations in Hematology ", 27/04/1907.
Theme: "von Willebrand disease: molecular biology, detection of mutations."

- theoretical and practical course "Update in Hemostasis and Thrombosis" by the Department of Haemostasis and Thrombosis, 13 to 14/9/2007. Module III: Von Willebrand factor, with a total of 10 hours lecture. Institute of Hematologic Research "Mariano R. Castex", National Academy of Medicine.
Topic: von Willebrand Factor. Von Willebrand disease, variants.
ristocetin cofactor activity in plasma and platelets. Aggregation with ristocetin. Biology
molecular vo Willebrand disease.
search techniques for mutation screening for VWD 2 N.

- Race Course organized by the Specialist in Clinical Biochemistry, Haematology area, 04.15.2008, Haemostasis Module "von Willebrand Factor, generalities. Von Willebrand disease, diagnosis and classification. Test ristocenina Cofactor of plasma and platelets. Aggregation with ristocetin. VWD molecular biology techniques, screening, sequencing.

PARTICIPATION IN RESEARCH PROJECTS

charge of sub-projects in the projects led by Dr Mary A. Lazzari described below: -1995
PID 332360092. PICT
0173 -1997 (PIP 4640/96). "Pared vascular, leukocytes, platelets and von Willebrand factor, its intervention
thrombosis." Project No. 05-00000-00706
ANPCyT -1998. "Physiology of platelets, leukocytes and endothelial cells mediated
cell interactions and von Willebrand factor." -1999
PIP CONICET Project No. 02066. "The von Willebrand factor. Its pathophysiological interactions.
von Willebrand disease"
-2000 ANPCyT Project PICT No. 8875. "Pathophysiology of humoral and cellular interactions in the vascular wall
." -2002
ANPCYT Project No. 0511270. Topic: "Structural alterations Factor von Willebrand endothelial cells produced by normal maternal plasma and purified proteases. Most common mutations and polymorphisms in the ADAMTS 13. " -2004
ANPCyT Project No. 25434. Topic:. ADAMTS-13: isolation, quantification in platelets (RT-PCR), pathologies and assessment models "in vivo" - "in vitro". -2004
PIP CONICET Project No. 6026. Topic: VWF and ADAMTS-13, molecular biology, quantification of mRNA in platelets. Similarity and difference in placental endothelium. Evaluation in human pathologies and animal models.

AWARDS OBTAINED

- Award of Masnatta Arini Elsa ", given by National Academy of Medicine. Buenos Aires, October 1988.
Topic: platelet disorders and the complex FVIII / von Willebrand factor in myelo-proliferative syndromes. Meschengieser S, Blanco A, Maugeri N, Woods A, Bermejo E, Dupont J, Fernandez J, Pieroni G, Lazzari MA

- Reach the Developing World Travel Grant. Awarded by the International Society on Thrombosis and Haemostasis. XIX Congress SSC and 49 ° Annual Meeting.
work won: Woods AI, Meschengieser SS, Blanco AN, Lazzari MA. Incidence of major haemorrhage related to surgery in type 1 von Willebrand's disease. XIX Congress and 49th Annual SSC Meeting. International Society on Thrombosis and Haemostasis. Birmingham, UK. jul12-18, 2003.

- Second Award Research Grant to ORT 2003 "Chemical ORT Project Human Genome" (95 points) with the theme "Diagnosis of von Willebrand disease (VWD) type 2N by genotypic and phenotypic techniques."

- Research Grant to ORT 2004 "Project Human Genome ORT Chemistry" with the theme "Diagnosis of von Willebrand disease (VWD) type 2N by genotypic and phenotypic techniques."

- Research Grant to ORT 2005 "Molecular Biology and Proteomics 2005" with the theme: VWF and ADAMTS-13: molecular biology.

- Grant for Research ORT 2006 in Molecular Biochemistry and Proteomics with the theme: Diagnosis of von Willebrand disease (VWD) type 2N by phenotypic and genotypic techniques.

- Research Grant to ORT 2007 in Molecular Biochemistry and Proteomics with the theme: "Study of ADAMTS-13 genotype in patients with thrombotic microangiopathy"

- Research Grant to ORT 2008 in Molecular Biochemistry and Proteomics with the theme: Diagnosis of von Willebrand disease (VWD) type 2N by phenotypic and genotypic techniques.

-
COLLABORATION IN BOOK CHAPTERS

Techniques Hemostasis and Thrombosis. Cooperative Group Latin American Hemostasis and Thrombosis, 2nd Edition. Editors: C. Campos Guerra, L. Kordich, JC Sanchez Avalos, O. Vidal.
- Detection of circulating platelet microaggregates: identification, interpretation and clinical utility.
- Ristocetin Cofactor: identification, interpretation and clinical utility.

Technical Manual. Institute of Hematologic Research "Mariano R. Castex", National Academy of Medicine. Editors: Luis J Bergner, Maria A Lazzari.
- Detection of circulating platelet microaggregates: detection, interpretation and clinical utility.
- Ristocetin Cofactor: identification, interpretation and utility clinic.
- platelet coagulant activity.

Foundations for the practical use in the laboratory of haemostasis. Argentinean Cooperative Group
Haemostasis and Thrombosis, 1 edition, 2003. Editor in Chief: Lucía Kordich. Chapter

Factor VIII: von Willebrand Factor:
- Ristocetin cofactor activity (VWF: RCo) in plasma. P. 295.
- intraplatelet von Willebrand factor. Ristocetin cofactor activity (VWF: RCo). P. 305. Chapter

Platelets Study Methodology:
- Determination of circulating platelet microaggregates. P. 124. VARIOUS



- Member of the Latin American Cooperative Group Haemostasis and Thrombosis (CLAHT) since 1980.

- Member of the Argentinean Cooperative Group of Haemostasis and Thrombosis (CAHT) since 1981.

- Concurrency to Henry Beaufour Research Institute, Paris, France, from 15 to 25/07/1987, which discussed various research projects with its Director, Dr. Eduardo Pirotski, concerning the effect of PAF and BN 52021 (its specific inhibitor) on the release of antiactivadores antiplasmin and plasminogen activator (PAI-1) of platelets.

- Secretary of the International Symposium on Thrombosis. Buenos Aires, Buenos Aires, 11/13 April 1988.